QUARTERLY REPORT

Q1 FY2025 — Quarterly report (Form 10-Q)

Q1 FY2025PDF · 67 pages832 KB
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-Q
(Mark one)
x True QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the Quarterly Period Ended September 30, 2024
OR
o False TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from 	to
THE PROCTER & GAMBLE COMPANY
(Exact name of registrant as specified in its charter)
Ohio 	OH 	1-434 	31-0411980
(State of Incorporation) 	(Commission File Number) 	(I.R.S. Employer Identification Number)
One Procter & Gamble Plaza 	Cincinnati 	OH
One Procter & Gamble Plaza, Cincinnati, Ohio 	45202
(Address of principal executive offices) 	(Zip Code)
(513) 983-1100
(Registrant’s telephone number, including area code)
Securities registered pursuant to Section 12(b) of the Act:
Title of each class 	Trading Symbol 	Name of each exchange on which registered
Common Stock, without Par Value 	PG 	NYSE
0.500% Notes due 2024 	PG24A 	NYSE
0.625% Notes due 2024 	PG24B 	NYSE
1.375% Notes due 2025 	PG25 	NYSE
0.110% Notes due 2026 	PG26D 	NYSE
3.250% EUR Notes due 2026 	PG26F 	NYSE
4.875% EUR Notes due May 2027 	PG27A 	NYSE
1.200% Notes due 2028 	PG28 	NYSE
3.150% EUR Notes due 2028 	PG28B 	NYSE
1.250% Notes due 2029 	PG29B 	NYSE
1.800% Notes due 2029 	PG29A 	NYSE
6.250% GBP Notes due January 2030 	PG30 	NYSE
0.350% Notes due 2030 	PG30C 	NYSE
0.230% Notes due 2031 	PG31A 	NYSE
3.250% EUR Notes due 2031 	PG31B 	NYSE
5.250% GBP Notes due January 2033 	PG33 	NYSE
3.200% EUR Notes due 2034 	PG34C 	NYSE
1.875% Notes due 2038 	PG38 	NYSE
0.900% Notes due 2041 	PG41 	NYSE
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such
shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes þ No o
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter)
during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
Yes þ No o
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of
"large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.
Large accelerated filer 	þ 	Accelerated filer 	¨
Non-accelerated filer 	¨ 	Smaller reporting company 	¨ 	False
Emerging growth company 	¨ 	False
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. ¨
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes o No þ False
There were 2,355,041,729 shares of Common Stock outstanding as of September 30, 2024.

-- 1 of 67 --

FORM 10-Q TABLE OF CONTENTS 	Page
PART I 	Item 1. 	Financial Statements 	1
Consolidated Statements of Earnings 	1
Consolidated Statements of Comprehensive Income 	1
Consolidated Balance Sheets 	2
Consolidated Statements of Shareholders' Equity 	3
Consolidated Statements of Cash Flows 	4
Notes to Consolidated Financial Statements 	5
Note 1: Basis of Presentation 	5
Note 2: New Accounting Pronouncements and Policies 	5
Note 3: Segment Information 	5
Note 4: Goodwill and Intangible Assets 	6
Note 5: Earnings Per Share 	8
Note 6: Share-Based Compensation and Postretirement Benefits 	8
Note 7: Risk Management Activities and Fair Value Measurements 	9
Note 8: Accumulated Other Comprehensive Income/(Loss) 	10
Note 9: Commitments and Contingencies 	10
Note 10: Supplier Finance Programs 	11
Note 11: Restructuring Program 	11
Item 2. 	Management's Discussion and Analysis of Financial Condition and Results of Operations 	12
Item 3. 	Quantitative and Qualitative Disclosures About Market Risk 	22
Item 4. 	Controls and Procedures 	22
PART II 	Item 1. 	Legal Proceedings 	23
Item 1A. 	Risk Factors 	24
Item 2. 	Unregistered Sales of Equity Securities, Use of Proceeds and Issuer Purchases of Equity Securities 	24
Item 5. 	Other Information 	24
Item 6. 	Exhibits 	25
Signature 	25

-- 2 of 67 --

The Procter & Gamble Company 1
PART I. FINANCIAL INFORMATION
Item 1. 	Financial Statements
THE PROCTER & GAMBLE COMPANY AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF EARNINGS
Three Months Ended September
30
Amounts in millions except per share amounts 	2024 	2023
NET SALES 	$ 	21,737 $ 	21,871
Cost of products sold 	10,421 	10,501
Selling, general and administrative expense 	5,519 	5,604
OPERATING INCOME 	5,797 	5,767
Interest expense 	(238) 	(225)
Interest income 	135 	128
Other non-operating income/(expense), net 	(554) 	132
EARNINGS BEFORE INCOME TAXES 	5,140 	5,802
Income taxes 	1,152 	1,246
NET EARNINGS 	3,987 	4,556
Less: Net earnings attributable to noncontrolling interests 	28 	35
NET EARNINGS ATTRIBUTABLE TO PROCTER & GAMBLE 	$ 	3,959 $ 	4,521
NET EARNINGS PER COMMON SHARE
Basic 	$ 	1.65 $ 	1.89
Diluted 	$ 	1.61 $ 	1.83
Basic net earnings per common share and Diluted net earnings per common share are calculated on Net earnings attributable to Procter & Gamble.
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
Three Months Ended September
30
Amounts in millions 	2024 	2023
NET EARNINGS 	$ 	3,987 $ 	4,556
OTHER COMPREHENSIVE INCOME/(LOSS), NET OF TAX
Foreign currency translation 	1,026 	(409)
Unrealized gains/(losses) on investment securities 	2 	(1)
Unrealized gains/(losses) on defined benefit postretirement plans 	(21) 	45
TOTAL OTHER COMPREHENSIVE INCOME/(LOSS), NET OF TAX 	1,007 	(366)
TOTAL COMPREHENSIVE INCOME 	4,994 	4,190
Less: Comprehensive income attributable to noncontrolling interests 	28 	33
TOTAL COMPREHENSIVE INCOME ATTRIBUTABLE TO PROCTER & GAMBLE 	$ 	4,965 $ 	4,157
(1)
(1)
See accompanying Notes to Consolidated Financial Statements.

-- 3 of 67 --

2 The Procter & Gamble Company
THE PROCTER & GAMBLE COMPANY AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
Amounts in millions 	September 30, 2024 	June 30, 2024
Assets
CURRENT ASSETS
Cash and cash equivalents 	$ 	12,156 $ 	9,482
Accounts receivable 	6,314 	6,118
INVENTORIES
Materials and supplies 	1,820 	1,617
Work in process 	921 	929
Finished goods 	4,546 	4,470
Total inventories 	7,287 	7,016
Prepaid expenses and other current assets 	1,692 	2,095
TOTAL CURRENT ASSETS 	27,449 	24,709
PROPERTY, PLANT AND EQUIPMENT, NET 	22,506 	22,152
GOODWILL 	40,970 	40,303
TRADEMARKS AND OTHER INTANGIBLE ASSETS, NET 	22,053 	22,047
OTHER NONCURRENT ASSETS 	13,503 	13,158
TOTAL ASSETS 	$ 	126,482 $ 	122,370
Liabilities and Shareholders' Equity
CURRENT LIABILITIES
Accounts payable 	$ 	15,350 $ 	15,364
Accrued and other liabilities 	10,661 	11,073
Debt due within one year 	10,409 	7,191
TOTAL CURRENT LIABILITIES 	36,420 	33,627
LONG-TERM DEBT 	25,744 	25,269
DEFERRED INCOME TAXES 	6,420 	6,516
OTHER NONCURRENT LIABILITIES 	5,757 	6,398
TOTAL LIABILITIES 	74,341 	71,811
SHAREHOLDERS’ EQUITY
Preferred stock 	791 	798
Common stock – shares issued – 	September 2024 	4,009.2
June 2024 	4,009.2 	4,009 	4,009
Additional paid-in capital 	68,102 	67,684
Reserve for ESOP debt retirement 	(707) 	(737)
Accumulated other comprehensive loss 	(10,893) 	(11,900)
Treasury stock 	(134,823) 	(133,379)
Retained earnings 	125,361 	123,811
Noncontrolling interest 	300 	272
TOTAL SHAREHOLDERS’ EQUITY 	52,141 	50,559
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY 	$ 	126,482 $ 	122,370
See accompanying Notes to Consolidated Financial Statements.

-- 4 of 67 --

The Procter & Gamble Company 3
THE PROCTER & GAMBLE COMPANY AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY
Three Months Ended September 30, 2024
Dollars in millions;
shares in thousands
Common Stock 	Preferred
Stock
Additional
Paid-In
Capital
Reserve for
ESOP Debt
Retirement
Accumulated
Other
Comprehensive
Income/(Loss) Treasury Stock
Retained
Earnings
Noncontrolling
Interest
Total
Shareholders'
Equity	Shares 	Amount
BALANCE JUNE 30, 2024 	2,357,051 $4,009 	$798 	$67,684 	($737) 	($11,900) ($133,379) 	$123,811 	$272 	$50,559
Net earnings 	3,959 	28 	3,987
Other comprehensive
income/(loss) 	1,006 	1 	1,007
Dividends and dividend
equivalents
($1.0065 per share):
Common 	(2,378) 	(2,378)
Preferred 	(72) 	(72)
Treasury stock purchases 	(11,552) 	(1,942) 	(1,942)
Employee stock plans 	8,769 	417 	492 	910
Preferred stock conversions 	774 	(7) 	1 	6 	—
ESOP debt impacts 	30 	41 	71
Noncontrolling interest, net 	— 	— 	—
BALANCE SEPTEMBER 30,
2024 	2,355,042 $4,009 	$791 	$68,102 	($707) 	($10,893) ($134,823) 	$125,361 	$300 	$52,141
Three Months Ended September 30, 2023
Dollars in millions;
shares in thousands
Common Stock 	Preferred
Stock
Additional
Paid-In
Capital
Reserve for
ESOP Debt
Retirement
Accumulated
Other
Comprehensive
Income/(Loss) Treasury Stock
Retained
Earnings
Noncontrolling
Interest
Total
Shareholders'
Equity	Shares 	Amount
BALANCE JUNE 30, 2023 	2,362,120 $4,009 	$819 	$66,556 	($821) 	($12,220) ($129,736) 	$118,170 	$288 	$47,065
Net earnings 	4,521 	35 	4,556
Other comprehensive
income/(loss) 	(363) 	(2) 	(366)
Dividends and dividend
equivalents
($0.9407 per share):
Common 	(2,225) 	(2,225)
Preferred 	(70) 	(70)
Treasury stock purchases 	(9,843) 	(1,508) 	(1,508)
Employee stock plans 	3,721 	265 	209 	474
Preferred stock conversions 	888 	(7) 	1 	6 	—
ESOP debt impacts 	39 	48 	87
Noncontrolling interest, net 	— 	— 	—
BALANCE SEPTEMBER 30,
2023 	2,356,886 $4,009 	$812 	$66,822 	($782) 	($12,583) ($131,029) 	$120,443 	$321 	$48,014
See accompanying Notes to Consolidated Financial Statements.

-- 5 of 67 --

4 The Procter & Gamble Company
THE PROCTER & GAMBLE COMPANY AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
Three Months Ended September 30
Amounts in millions 	2024 	2023
CASH, CASH EQUIVALENTS AND RESTRICTED CASH, BEGINNING OF PERIOD 	$ 	9,482 $ 	8,246
OPERATING ACTIVITIES
Net earnings 	3,987 	4,556
Depreciation and amortization 	728 	702
Share-based compensation expense 	105 	125
Deferred income taxes 	184 	102
Loss/(gain) on sale of assets 	794 	(3)
Change in accounts receivable 	(134) 	(830)
Change in inventories 	(188) 	(142)
Change in accounts payable and accrued and other liabilities 	(648) 	857
Change in other operating assets and liabilities 	(558) 	(671)
Other 	32 	208
TOTAL OPERATING ACTIVITIES 	4,302 	4,904
INVESTING ACTIVITIES
Capital expenditures 	(993) 	(925)
Proceeds from asset sales 	45 	3
Acquisitions, net of cash acquired 	(6) 	—
Other investing activity 	(154) 	(300)
TOTAL INVESTING ACTIVITIES 	(1,108) 	(1,222)
FINANCING ACTIVITIES
Dividends to shareholders 	(2,445) 	(2,290)
Additions to short-term debt with original maturities of more than three months 	4,090 	2,179
Reductions in short-term debt with original maturities of more than three months 	(571) 	(1,906)
Net additions/(reductions) to other short-term debt 	(444) 	2,172
Reductions in long-term debt 	(70) 	(1,004)
Treasury stock purchases 	(1,939) 	(1,500)
Impact of stock options and other 	745 	312
TOTAL FINANCING ACTIVITIES 	(634) 	(2,038)
EFFECT OF EXCHANGE RATE CHANGES ON CASH, CASH EQUIVALENTS AND RESTRICTED CASH 	116 	(156)
CHANGE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH 	2,675 	1,487
CASH, CASH EQUIVALENTS AND RESTRICTED CASH, END OF PERIOD 	$ 	12,156 $ 	9,733
See accompanying Notes to Consolidated Financial Statements.

-- 6 of 67 --

The Procter & Gamble Company 5
THE PROCTER & GAMBLE COMPANY AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
1. Basis of Presentation
The accompanying unaudited Consolidated Financial Statements of The Procter & Gamble Company and subsidiaries ("the Company," "Procter & Gamble,"
"P&G," "we" or "our") should be read in conjunction with the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2024. We have
prepared these statements in conformity with accounting principles generally accepted in the United States (U.S. GAAP) pursuant to the rules and regulations
of the U.S. Securities and Exchange Commission (SEC) for interim financial information. Note that certain columns and rows may not add due to rounding. In
the opinion of management, the accompanying Consolidated Financial Statements contain all normal recurring adjustments necessary to present fairly the
financial position, results of operations and cash flows for the interim periods reported. However, the results of operations included in such financial statements
may not necessarily be indicative of annual results.
2. New Accounting Pronouncements and Policies
In November 2023, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2023-07, “Segment Reporting:
Improvements to Reportable Segment Disclosures.” This guidance requires disclosure of incremental segment information on an annual and interim basis. This
amendment is effective for our fiscal year ending June 30, 2025 and our interim periods within the fiscal year ending June 30, 2026. The guidance will require
additional disclosures in the Segment Information footnote, but will not have a material impact on our Consolidated Financial Statements.
In December 2023, the FASB issued ASU No. 2023-09, “Income Taxes: Improvements to Income Tax Disclosures.” This guidance requires consistent
categories and greater disaggregation of information in the rate reconciliation and disclosures of income taxes paid by jurisdiction. This amendment is effective
for our fiscal year ending June 30, 2026. We are currently assessing the impact of this guidance on our disclosures.
No other new accounting pronouncement issued or effective during the fiscal year had, or is expected to have, a material impact on our Consolidated Financial
Statements.
3. Segment Information
Under U.S. GAAP, our operating segments are aggregated into five reportable segments: 1) Beauty, 2) Grooming, 3) Health Care, 4) Fabric & Home Care and
5) Baby, Feminine & Family Care. Our five reportable segments are comprised of:
• Beauty: Hair Care (Conditioners, Shampoos, Styling Aids, Treatments); Personal Care (Antiperspirants and Deodorants, Personal Cleansing); Skin Care
(Facial Moisturizers, Cleaners and Treatments);
• Grooming: Grooming (Appliances, Female Blades & Razors, Male Blades & Razors, Pre- and Post-Shave Products, Other Grooming);
• Health Care: Oral Care (Toothbrushes, Toothpaste, Other Oral Care); Personal Health Care (Gastrointestinal, Pain Relief, Rapid Diagnostics, Respiratory,
Vitamins/Minerals/Supplements, Other Personal Health Care);
• Fabric & Home Care: Fabric Care (Fabric Enhancers, Laundry Additives, Laundry Detergents); Home Care (Air Care, Dish Care, P&G Professional,
Surface Care); and
• Baby, Feminine & Family Care: Baby Care (Baby Wipes, Taped Diapers and Pants); Feminine Care (Adult Incontinence, Menstrual Care); Family Care
(Paper Towels, Tissues, Toilet Paper).
Amounts in millions of dollars except per share amounts or as otherwise specified.

-- 7 of 67 --

6 The Procter & Gamble Company
Operating segments as a percentage of consolidated net sales are as follows:
% of Net sales by operating segment
Three Months Ended September 30
2024 	2023
Fabric Care 	23 % 	23 %
Home Care 	13 % 	12 %
Baby Care 	9 % 	9 %
Hair Care 	9 % 	9 %
Family Care 	8 % 	8 %
Grooming 	8 % 	8 %
Oral Care 	8 % 	8 %
Personal Health Care 	7 % 	6 %
Feminine Care 	6 % 	7 %
Personal Care 	6 % 	6 %
Skin Care 	3 % 	4 %
Total 	100 % 	100 %
% of Net sales by operating segment excludes sales recorded in Corporate.
Effective July 1, 2024, the Beauty reportable business segment separated Skin and Personal Care into individual operating segments, Skin Care and Personal Care. This
transition included separation of the management team, strategic decision-making, innovation plans, financial targets, budgets and management reporting.
The following is a summary of reportable segment results:
Three Months Ended September 30
Net Sales Earnings/(Loss)
Before Income Taxes Net
Earnings/(Loss)
Beauty 	2024 $ 	3,892 $ 	1,067 $ 	840
2023 	4,097 	1,249 	971
Grooming 	2024 	1,723 	522 	426
2023 	1,724 	533 	421
Health Care 	2024 	3,147 	953 	741
2023 	3,074 	889 	689
Fabric & Home Care 	2024 	7,710 	2,077 	1,621
2023 	7,646 	2,031 	1,569
Baby, Feminine & Family Care 	2024 	5,102 	1,383 	1,066
2023 	5,186 	1,408 	1,075
Corporate 	2024 	163 	(862) 	(707)
2023 	144 	(308) 	(168)
Total Company 	2024 $ 	21,737 $ 	5,140 $ 	3,987
2023 	21,871 	5,802 	4,556
4. Goodwill and Intangible Assets
Goodwill is allocated by reportable segment as follows:
Beauty 	Grooming 	Health Care
Fabric & Home
Care
Baby, Feminine &
Family Care 	Total Company
Goodwill at June 30, 2024 	$ 	13,723 $ 	12,633 $ 	7,638 $ 	1,810 $ 	4,499 $ 	40,303
Acquisitions and divestitures 	— 	— 	— 	— 	— 	—
Translation and other 	251 	179 	151 	20 	67 	667
Goodwill at September 30, 2024 	$ 	13,974 $ 	12,812 $ 	7,789 $ 	1,831 $ 	4,566 $ 	40,970
Goodwill increased from June 30, 2024, primarily due to currency translation.
(1)
(2)
(2)
(1)
(2)
Amounts in millions of dollars except per share amounts or as otherwise specified.

-- 8 of 67 --

The Procter & Gamble Company 7
Identifiable intangible assets at September 30, 2024, were comprised of:
Gross Carrying Amount 	Accumulated Amortization
Intangible assets with determinable lives 	$ 	9,107 	$ 	(6,700)
Intangible assets with indefinite lives 	19,646 	—
Total identifiable intangible assets 	$ 	28,754 	$ 	(6,700)
Intangible assets with determinable lives consist of brands, patents, technology and customer relationships. The intangible assets with indefinite lives primarily
consist of brands. The amortization expense of determinable-lived intangible assets for the three months ended September 30, 2024 and 2023, was $83 and
$87, respectively.
Goodwill and indefinite-lived intangible assets are not amortized but are tested at least annually for impairment. We use the income method to estimate the fair
value of these assets, which is based on forecasts of the expected future cash flows attributable to the respective assets. When appropriate, the market approach,
which leverages comparable company revenue and earnings multiples, is weighted with the income approach to estimate fair value. If the resulting fair value is
less than the asset's carrying value, that difference represents an impairment. Our annual impairment testing for goodwill and indefinite-lived intangible assets
occurs during the three months ended December 31. Other than our Gillette indefinite-lived intangible asset, our goodwill reporting units and indefinite-lived
intangible assets have fair values that significantly exceed their underlying carrying values.
As previously disclosed, the carrying value of the Gillette indefinite-lived intangible asset was impaired during the year ended June 30, 2024. The impairment
charge arose due to a higher discount rate, weakening of several currencies relative to the U.S. dollar and the impact of a new restructuring program focused
primarily in certain Enterprise Markets, including Argentina and Nigeria. Following the impairment charge, the carrying value of the Gillette indefinite-lived
intangible asset was $12.8 billion, which was equivalent to the estimated fair value as of December 31, 2023.
While we have concluded that no triggering event has occurred during the quarter ended September 30, 2024, the Gillette indefinite-lived intangible asset is
susceptible to further impairment risk. Adverse changes in the business or in the macroeconomic environment, including foreign currency devaluation,
increasing global inflation, or market contraction from an economic recession, could reduce the underlying cash flows used to estimate the fair value of the
Gillette indefinite-lived intangible asset and trigger a further impairment charge.
The most significant assumptions utilized in the determination of the estimated fair value of the Gillette indefinite-lived intangible asset are the net sales
growth rates (including residual growth rates), discount rate and royalty rates.
Net sales growth rates could be negatively impacted by reductions or changes in demand for our Gillette products, which may be caused by, among other
things: changes in the use and frequency of grooming products, shifts in demand away from one or more of our higher priced products to lower priced products
or potential supply chain constraints. In addition, relative global and country/regional macroeconomic factors could result in additional and prolonged
devaluation of other countries' currencies relative to the U.S. dollar. The residual growth rates represent the expected rate at which the Gillette brand is
expected to grow beyond the shorter-term business planning period. The residual growth rates utilized in our fair value estimates are consistent with the brand
operating plans and approximate expected long-term category market growth rates. The residual growth rate depends on overall market growth rates, the
competitive environment, inflation, relative currency exchange rates and business activities that impact market share. As a result, the residual growth rate could
be adversely impacted by a sustained deceleration in category growth, grooming habit changes, devaluation of currencies against the U.S. dollar or an increased
competitive environment.
The discount rate, which is consistent with a weighted average cost of capital that is likely to be expected by a market participant, is based upon industry
required rates of return, including consideration of both debt and equity components of the capital structure. Our discount rate may be impacted by adverse
changes in the macroeconomic environment, volatility in the equity and debt markets or other country specific factors, such as further devaluation of currencies
against the U.S. dollar. Spot rates as of the fair value measurement date are utilized in our fair value estimates for cash flows outside the U.S.
The royalty rate used to determine the estimated fair value for the Gillette indefinite-lived intangible asset is driven by historical and estimated future
profitability of the underlying Gillette business. The royalty rate may be impacted by significant adverse changes in long-term operating margins.
Amounts in millions of dollars except per share amounts or as otherwise specified.

-- 9 of 67 --

8 The Procter & Gamble Company
We performed a sensitivity analysis for the Gillette indefinite-lived intangible asset as part of our annual impairment testing during the three months ended
December 31, 2023, utilizing reasonably possible changes in the assumptions for the discount rate, the short-term and residual growth rates and the royalty rate
to demonstrate the potential impacts to estimated fair values. The table below provides, in isolation, the estimated fair value impacts related to a 25 basis-point
increase in the discount rate, a 25 basis-point decrease in our short-term and residual growth rates or a 50 basis-point decrease in our royalty rate, which may
result in an additional impairment of the Gillette indefinite-lived intangible asset.
Approximate Percent Change in Estimated Fair Value
+25 bps Discount Rate 	-25 bps Growth Rates 	-50 bps Royalty Rate
Gillette indefinite-lived intangible asset 	(5)% 	(5)% 	(4)%
5. Earnings Per Share
Basic net earnings per common share are calculated by dividing Net earnings attributable to Procter & Gamble less preferred dividends by the weighted
average number of common shares outstanding during the period. Diluted net earnings per common share are calculated by dividing Net earnings attributable
to Procter & Gamble by the diluted weighted average number of common shares outstanding during the period. The diluted shares include the dilutive effect of
stock options and other share-based awards based on the treasury stock method and the assumed conversion of preferred stock.
Net earnings per common share were calculated as follows:
CONSOLIDATED AMOUNTS Three Months Ended September
30
2024 	2023
Net earnings 	$ 	3,987 $ 	4,556
Less: Net earnings attributable to noncontrolling interests 	28 	35
Net earnings attributable to P&G 	3,959 	4,521
Less: Preferred dividends 	72 	70
Net earnings attributable to P&G available to common shareholders (Basic) 	$ 	3,887 $ 	4,450
SHARES IN MILLIONS
Basic weighted average common shares outstanding 	2,356.2 	2,360.0
Add effect of dilutive securities:
Convertible preferred shares 	71.9 	74.6
Stock options and other unvested equity awards 	37.9 	40.6
Diluted weighted average common shares outstanding 	2,466.0 	2,475.2
NET EARNINGS PER COMMON SHARE
Basic 	$ 	1.65 $ 	1.89
Diluted 	$ 	1.61 $ 	1.83
An overview of preferred shares can be found in our Annual Report on Form 10-K for the fiscal year ended June 30, 2024.
Excludes approximately 1 million for the three months ended September 30, 2024 and 2023 respectively, of weighted average stock options outstanding because the
exercise price of these options was greater than their average market value or their effect was antidilutive.
6. Share-Based Compensation and Postretirement Benefits
The following table provides a summary of our share-based compensation expense and postretirement benefit impacts:
Three Months Ended September
30
2024 	2023
Share-based compensation expense 	$ 	105 $ 	125
Net periodic benefit cost for pension benefits 	37 	57
Net periodic benefit (credit) for other retiree benefits 	(180) 	(156)
(1)
(2)
(1)
(2)
Amounts in millions of dollars except per share amounts or as otherwise specified.

-- 10 of 67 --

The Procter & Gamble Company 9
7. Risk Management Activities and Fair Value Measurements
As a multinational company with diverse product offerings, we are exposed to market risks, such as changes in interest rates, currency exchange rates and
commodity prices. There have been no significant changes in our risk management policies or activities during the three months ended September 30, 2024.
The Company has not changed its valuation techniques used in measuring the fair value of any financial assets and liabilities during the period. The Company
recognizes transfers between levels within the fair value hierarchy, if any, at the end of each quarter. There were no transfers between levels during the periods
presented. Also, there was no significant activity within the Level 3 assets and liabilities during the periods presented. Except for the impairment of the Gillette
indefinite-lived intangible asset discussed in Note 4, there were no significant assets or liabilities that were re-measured at fair value on a non-recurring basis
during the three months ended September 30, 2024 or during the fiscal year ended June 30, 2024.
Cash equivalents were $10.7 billion and $8.0 billion as of September 30, 2024 and June 30, 2024, respectively, and are classified as Level 1 within the fair
value hierarchy. The Company had no other material investments in debt or equity securities during the periods presented.
The fair value of long-term debt was $29.0 billion and $27.7 billion as of September 30, 2024 and June 30, 2024, respectively. This includes the current portion
of long-term debt instruments ($3.9 billion and $3.8 billion as of September 30, 2024 and June 30, 2024, respectively). Certain long-term debt (debt designated
as a fair value hedge) is recorded at fair value. All other long-term debt is recorded at amortized cost but is measured at fair value for disclosure purposes. We
consider our debt to be Level 2 in the fair value hierarchy. Fair values are generally estimated based on quoted market prices for identical or similar
instruments.
Disclosures about Financial Instruments
The notional amounts and fair values of financial instruments used in hedging transactions as of September 30, 2024 and June 30, 2024, are as follows:
Notional Amount 	Fair Value Asset 	Fair Value (Liability)
September 30, 2024 June 30, 2024 	September 30, 2024 June 30, 2024 September 30, 2024 June 30, 2024
DERIVATIVES IN FAIR VALUE HEDGING RELATIONSHIPS
Interest rate contracts 	$ 	3,127 $ 	2,993 $ 	— $ 	— $ 	(249) $ 	(325)
DERIVATIVES IN NET INVESTMENT HEDGING RELATIONSHIPS
Foreign currency interest rate contracts 	$ 	12,531 $ 	10,140 $ 	— $ 	119 $ 	(310) $ 	(31)
TOTAL DERIVATIVES DESIGNATED AS
HEDGING INSTRUMENTS 	$ 	15,658 $ 	13,133 $ 	— $ 	119 $ 	(559) $ 	(356)
DERIVATIVES NOT DESIGNATED AS HEDGING INSTRUMENTS
Foreign currency contracts 	$ 	3,900 $ 	3,192 $ 	36 $ 	1 $ 	(3) $ 	(23)
TOTAL DERIVATIVES AT FAIR VALUE 	$ 	19,558 $ 	16,325 $ 	36 $ 	120 $ 	(562) $ 	(379)
The fair value of the interest rate derivative asset/(liability) directly offsets the cumulative amount of the fair value hedging adjustment included in the carrying
amount of the underlying debt obligation. The carrying amount of the underlying debt obligation, which includes the unamortized discount or premium and the
fair value adjustment, was $2.9 billion and $2.7 billion as of September 30, 2024 and June 30, 2024, respectively. In addition to the foreign currency derivative
contracts designated as net investment hedges, certain of our foreign currency denominated debt instruments are designated as net investment hedges. The
carrying value of those debt instruments designated as net investment hedges, which includes the adjustment for the foreign currency transaction gain or loss on
those instruments, was $12.6 billion and $11.9 billion as of September 30, 2024 and June 30, 2024, respectively. The increase in notional balance of the
derivative instruments designated as net investment hedges is primarily driven by the Company's decision to leverage favorable interest rate spreads in the
foreign currency swap market.
Derivative assets are presented in Prepaid expenses and other current assets or Other noncurrent assets. Derivative liabilities are presented in Accrued and other
liabilities or Other noncurrent liabilities. Changes in the fair value of net investment hedges are recognized in the Foreign currency translation component of
Other comprehensive income (OCI). All of the Company's derivative assets and liabilities measured at fair value are classified as Level 2 within the fair value
hierarchy.
Certain of the Company's financial instruments used in hedging transactions are governed by industry standard netting and collateral agreements with
counterparties. If the Company's credit rating were to fall below the levels stipulated in the agreements, the counterparties could demand either collateralization
or termination of the arrangements. The aggregate fair value of the instruments covered by these contractual features that are in a liability position was $559
and $307 as of
Amounts in millions of dollars except per share amounts or as otherwise specified.

-- 11 of 67 --

10 The Procter & Gamble Company
September 30, 2024 and June 30, 2024, respectively. The Company has not been required to post collateral as a result of these contractual features.
Before tax gains and losses on our financial instruments in hedging relationships are categorized as follows:
Amount of Gain/(Loss) Recognized in OCI on
Derivatives
Three Months Ended September 30
2024 	2023
DERIVATIVES IN NET INVESTMENT HEDGING RELATIONSHIPS
Foreign currency interest rate contracts 	$ 	(501) $ 	285
For the derivatives in net investment hedging relationships, the amount of gain excluded from effectiveness testing, which was recognized in earnings, was $50 and $67 for
the three months ended September 30, 2024 and 2023, respectively.
In addition to the foreign currency derivative contracts designated as net investment hedges, certain of our foreign currency denominated debt instruments are designated as
net investment hedges. The amount of gain/(loss) recognized in Accumulated other comprehensive income (AOCI) for such instruments was $(611) and $344 for the three
months ended September 30, 2024 and 2023, respectively.
Amount of Gain/(Loss) Recognized in Earnings
Three Months Ended September 30
2024 	2023
DERIVATIVES IN FAIR VALUE HEDGING RELATIONSHIPS
Interest rate contracts 	$ 	76 $ 	11
DERIVATIVES NOT DESIGNATED AS HEDGING INSTRUMENTS
Foreign currency contracts 	$ 	126 $ 	(71)
The gains on the derivatives in fair value hedging relationships are fully offset by the mark-to-market impact of the related exposure. These are both recognized
in Interest expense. The gains/(losses) on derivatives not designated as hedging instruments are substantially offset by the currency mark-to-market of the
related exposure. These are both recognized in Selling, general and administrative expense (SG&A).
8. Accumulated Other Comprehensive Income/(Loss)
The table below presents the changes in Accumulated other comprehensive income/(loss) attributable to Procter & Gamble (AOCI), including the
reclassifications out of AOCI by component:
Investment
Securities
Postretirement
Benefit Plans
Foreign Currency
Translation 	Total AOCI
Balance at June 30, 2024, net of tax 	$ 	10 $ 	613 $ 	(12,522) $ 	(11,900)
Other comprehensive income/(loss), before tax:
OCI before reclassifications 	2 	(15) 	13 	(1)
Amounts reclassified to the Consolidated Statement of Earnings 	— 	(14) 	752 	738
Total other comprehensive income/(loss), before tax 	2 	(29) 	765 	737
Tax effect 	— 	8 	261 	269
Total other comprehensive income/(loss), net of tax 	2 	(21) 	1,026 	1,007
Less: OCI attributable to noncontrolling interests, net of tax 	— 	1 	— 	1
Balance at September 30, 2024, net of tax 	$ 	12 $ 	591 $ 	(11,496) $ 	(10,893)
The below provides additional details on amounts reclassified from AOCI into the Consolidated Statement of Earnings:
• Postretirement benefit plan amounts are reclassified from AOCI into Other non-operating income/(expense) and included in the computation of net
periodic postretirement costs.
• Foreign currency translation amounts are reclassified from AOCI into Other non-operating income/(expense). These amounts relate to accumulated
foreign currency translation losses recognized due to the substantial liquidation of operations in certain Enterprise Markets, including Argentina.
9. Commitments and Contingencies
Litigation
We are subject, from time to time, to certain legal proceedings and claims arising out of our business, which cover a wide range of matters, including antitrust
and trade regulation, product liability, advertising, contracts, environmental, patent and trademark matters, labor and employment matters and tax. While
considerable uncertainty exists, in the opinion of management and our
(1) (2)
(1)
(2)
Amounts in millions of dollars except per share amounts or as otherwise specified.

-- 12 of 67 --

The Procter & Gamble Company 11
counsel, the ultimate resolution of the various lawsuits and claims will not materially affect our financial position, results of operations or cash flows.
We are also subject to contingencies pursuant to environmental laws and regulations that in the future may require us to take action to correct the effects on the
environment of prior manufacturing and waste disposal practices. Based on currently available information, we do not believe the ultimate resolution of
environmental remediation will materially affect our financial position, results of operations or cash flows.
Income Tax Uncertainties
The Company is present in approximately 70 countries and over 150 taxable jurisdictions and, at any point in time, has 30–40 jurisdictional audits underway at
various stages of completion. We evaluate our tax positions and establish liabilities for uncertain tax positions that may be challenged by local authorities and
may not be fully sustained, despite our belief that the underlying tax positions are fully supportable. Uncertain tax positions are reviewed on an ongoing basis
and are adjusted in light of changing facts and circumstances, including progress of tax audits, developments in case law and closing of statutes of limitations.
Such adjustments are reflected in the tax provision as appropriate. We have tax years open ranging from 2010 and forward. We are generally not able to reliably
estimate the timing and ultimate settlement amounts until the close of an audit. Based on information currently available, we do not anticipate over the next 12-
month period any significant audit activity concluding related to uncertain tax positions for which we have existing accrued liabilities.
Additional information on the Commitments and Contingencies of the Company can be found in our Annual Report on Form 10-K for the fiscal year ended
June 30, 2024.
10. Supplier Finance Programs
The Company has an ongoing program to negotiate extended payment terms with its suppliers consistent with market practices. The Company also supports a
Supply Chain Finance program (“SCF”) with several global financial institutions. Under SCF, the Company maintains an accounts payable system to facilitate
participating suppliers' ability to sell receivables from the Company to a SCF bank. These participating suppliers negotiate their sales of receivables
arrangements directly with the respective SCF bank. The Company is not party to those agreements, but the SCF banks allow the suppliers to utilize the
Company’s creditworthiness in establishing credit spreads and associated costs. Under this model, this arrangement generally provides the suppliers with more
favorable terms than they would be able to secure on their own. The Company has no economic interest in a supplier’s decision to sell a receivable. Once a
qualifying supplier chooses to participate in SCF, the supplier selects which individual Company invoices to sell to the SCF bank. The Company’s obligations
to its suppliers, including the amounts due and scheduled payment dates, are not impacted by the supplier’s decisions to finance amounts under these
arrangements. The Company does not provide any form of guarantee under these financing arrangements. Our payment terms for suppliers under this program
generally range from 60 to 180 days. All outstanding amounts related to suppliers participating in SCF are recorded within Accounts payable in our
Consolidated Balance Sheets, and the associated payments are included in operating activities within our Consolidated Statements of Cash Flows. The amount
due to suppliers participating in SCF and included in Accounts payable was approximately $5.7 billion as of September 30, 2024 and $5.6 billion as of June 30,
2024.
11. Restructuring Program
The Company has historically incurred an ongoing annual level of restructuring-type activities to maintain a competitive cost structure, including
manufacturing and workforce optimization. Before tax costs incurred under the ongoing program have generally ranged from $250 to $500 annually.
Consistent with our historical policies for restructuring-type activities, the restructuring program charges will be funded by and included within Corporate for
management and segment reporting.
In the fiscal year ended June 30, 2024, the Company started a limited market portfolio restructuring of its business operations, primarily in certain Enterprise
Markets, including Argentina and Nigeria, to address challenging macroeconomic and fiscal conditions. During the period ended September 30, 2024, the
Company completed this limited market portfolio restructuring with the substantial liquidation of its operations in Argentina and recorded approximately
$0.8 billion after tax of incremental charges, comprised primarily of non-cash charges for accumulated foreign currency translation losses previously included
in Accumulated other comprehensive income/(loss). The total incremental restructuring charges incurred under the program beginning in the three-month
period ended December 31, 2023, through the three-month period ended September 30, 2024, were approximately $1.2 billion after tax.
For the three months ended September 30, 2024, the Company incurred total before tax charges of $886 including $41 in Costs of products sold, $54 in SG&A
and $791 in Other non-operating income/(expense).
Amounts in millions of dollars except per share amounts or as otherwise specified.

-- 13 of 67 --

12 The Procter & Gamble Company
The following table presents restructuring activity for the three months ended September 30, 2024:
Separation Costs 	Asset-Related Costs 	Other Costs 	Total
RESERVE JUNE 30, 2024 	$ 	133 $ 	— $ 	32 $ 	166
Costs incurred for the three months ended September 30, 2024 	16 	30 	839 	886
Costs paid/settled for the three months ended September 30, 2024 	(33) 	(30) 	(815) 	(879)
RESERVE SEPTEMBER 30, 2024 	$ 	116 $ 	— $ 	56 $ 	172
Separation Costs
Employee separation costs relate to severance packages that are primarily voluntary and the amounts calculated are based on salary levels and past service
periods.
Asset-Related Costs
Asset-related costs consist of both asset write-downs and accelerated depreciation for manufacturing consolidations. Asset write-downs relate to the
establishment of a new fair value basis for assets held-for-sale or for disposal. These assets are written down to the lower of their current carrying basis or
amounts expected to be realized upon disposal, less minor disposal costs. Charges for accelerated depreciation relate to long-lived assets that will be taken out
of service prior to the end of their normal service period.
Other Costs
Other restructuring-type charges are incurred as a direct result of the restructuring plan. Such charges include accumulated foreign currency translation losses,
asset removal and termination of contracts related to Enterprise Market portfolio restructuring.
Item 2. 	Management's Discussion and Analysis of Financial Condition and Results of Operations
Forward-Looking Statements
Certain statements in this report, other than purely historical information, including estimates, projections, statements relating to our business plans, objectives
and expected operating results, and the assumptions upon which those statements are based, are “forward-looking statements” within the meaning of the
Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-
looking statements may appear throughout this report, including without limitation, the following sections: “Management's Discussion and Analysis,” “Risk
Factors” and "Notes 4 and 9 to the Consolidated Financial Statements." These forward-looking statements generally are identified by the words “believe,”
“project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,”
“will likely result” and similar expressions. Forward-looking statements are based on current expectations and assumptions, which are subject to risks and
uncertainties that may cause results to differ materially from those expressed or implied in the forward-looking statements. We undertake no obligation to
update or revise publicly any forward-looking statements, whether because of new information, future events or otherwise, except to the extent required by law.
Risks and uncertainties to which our forward-looking statements are subject include, without limitation: (1) the ability to successfully manage global financial
risks, including foreign currency fluctuations, currency exchange or pricing controls; (2) the ability to successfully manage local, regional or global economic
volatility, including reduced market growth rates, and to generate sufficient income and cash flow to allow the Company to effect the expected share
repurchases and dividend payments; (3) the ability to successfully manage uncertainties related to changing political and geopolitical conditions and potential
implications such as exchange rate fluctuations, market contraction, boycotts, sanctions or other trade controls; (4) the ability to manage disruptions in credit
markets or to our banking partners or changes to our credit rating; (5) the ability to maintain key manufacturing and supply arrangements (including execution
of supply chain optimizations and sole supplier and sole manufacturing plant arrangements) and to manage disruption of business due to various factors,
including ones outside of our control, such as natural disasters, acts of war or terrorism or disease outbreaks; (6) the ability to successfully manage cost
fluctuations and pressures, including prices of commodities and raw materials and costs of labor, transportation, energy, pension and healthcare; (7) the ability
to compete with our local and global competitors in new and existing sales channels, including by successfully responding to competitive factors such as
prices, promotional incentives and trade terms for products; (8) the ability to manage and maintain key customer relationships; (9) the ability to protect our
reputation and brand equity by successfully managing real or perceived issues, including concerns about safety, quality, ingredients, efficacy, packaging
content, supply chain practices or similar matters that may arise; (10) the ability to successfully manage the financial, legal, reputational and operational risk
associated with third-party relationships, such as our suppliers, contract manufacturers, distributors, contractors and external business partners; (11) the ability
to rely on and maintain key company and third-party information and operational technology systems, networks and services and maintain the security and
functionality of such systems, networks and services and the data contained therein; (12) the ability to successfully manage the demand, supply and operational
challenges, as well as governmental responses or mandates, associated with a disease outbreak, including
Amounts in millions of dollars except per share amounts or as otherwise specified.

-- 14 of 67 --

The Procter & Gamble Company 13
epidemics, pandemics or similar widespread public health concerns; (13) the ability to stay on the leading edge of innovation, obtain necessary intellectual
property protections and successfully respond to changing consumer habits, evolving digital marketing and selling platform requirements and technological
advances attained by, and patents granted to, competitors; (14) the ability to successfully manage our ongoing acquisition, divestiture and joint venture
activities, in each case to achieve the Company’s overall business strategy and financial objectives, without impacting the delivery of base business objectives;
(15) the ability to successfully achieve productivity improvements and cost savings and manage ongoing organizational changes while successfully identifying,
developing and retaining key employees, including in key growth markets where the availability of skilled or experienced employees may be limited; (16) the
ability to successfully manage current and expanding regulatory and legal requirements and matters (including, without limitation, those laws and regulations
involving product liability, product and packaging composition, manufacturing processes, intellectual property, labor and employment, antitrust, privacy,
cybersecurity and data protection, artificial intelligence, tax, the environment, due diligence, risk oversight, accounting and financial reporting) and to resolve
new and pending matters within current estimates; (17) the ability to manage changes in applicable tax laws and regulations; and (18) the ability to successfully
achieve our ambition of reducing our greenhouse gas emissions and delivering progress towards our environmental sustainability priorities. A detailed
discussion of risks and uncertainties that could cause actual results and events to differ materially from those projected herein is included in the section titled
"Economic Conditions and Uncertainties" and the section titled "Risk Factors" (Part II, Item 1A) of this Form 10-Q.
Purpose, Approach and Non-GAAP Measures
The purpose of Management's Discussion and Analysis (MD&A) is to provide an understanding of Procter & Gamble's financial condition, results of
operations and cash flows by focusing on changes in certain key measures from year to year. The MD&A is provided as a supplement to, and should be read in
conjunction with, our Consolidated Financial Statements and accompanying Notes.
The MD&A is organized in the following sections:
• Overview
• Summary of Results – Three Months Ended September 30, 2024
• Economic Conditions and Uncertainties
• Results of Operations – Three Months Ended September 30, 2024
• Segment Results – Three Months Ended September 30, 2024
• Liquidity and Capital Resources
• Measures Not Defined by U.S. GAAP
Throughout the MD&A we refer to measures used by management to evaluate performance, including unit volume growth, net sales, net earnings, diluted net
earnings per common share (diluted EPS) and operating cash flow. We also refer to a number of financial measures that are not defined under U.S. GAAP,
consisting of organic sales growth, Core earnings per share (Core EPS), adjusted free cash flow and adjusted free cash flow productivity. The explanation at the
end of the MD&A provides the definition of these non-GAAP measures, details on the use and the derivation of these measures, as well as reconciliations to
the most directly comparable U.S. GAAP measure.
Management also uses certain market share and market consumption estimates to evaluate performance relative to competition despite some limitations on the
availability and comparability of share and consumption information. References to market share and consumption in the MD&A are based on a combination
of vendor-purchased traditional brick-and-mortar and online data in key markets as well as internal estimates. All market share references represent the
percentage of sales of our products in dollar terms on a constant currency basis relative to all product sales in the category. The Company measures quarter to
date market share through the most recent period for which market share data is available, which typically reflects a lag time of one or two months as compared
to the end of the reporting period. Management also uses unit volume growth to evaluate drivers of changes in net sales. Organic volume growth reflects year-
over-year changes in unit volume excluding the impacts of acquisitions and divestitures and certain one-time items, if applicable, and is used to explain
changes in organic sales. Certain columns and rows may not add due to rounding.
OVERVIEW
P&G is a global leader in the fast-moving consumer goods industry, focused on providing branded consumer packaged goods of superior quality and value to
our consumers around the world. Our products are sold in approximately 180 countries and territories, primarily through mass merchandisers, e-commerce
(including social commerce) channels, grocery stores, membership club stores, drug stores, department stores, distributors, wholesalers, specialty beauty stores
(including airport duty-free stores), high-frequency stores, pharmacies, electronics stores and professional channels. We also sell direct to individual
consumers. We have on-the-ground operations in approximately 70 countries.
Our market environment is highly competitive with global, regional and local competitors. In many of the markets and industry segments in which we sell our
products, we compete against other branded products as well as retailers' private-label brands. Additionally, many of the product segments in which we
compete are differentiated by price tiers (referred to as super-

-- 15 of 67 --

14 The Procter & Gamble Company
premium, premium, mid-tier and value-tier products). We believe we are well positioned in the industry segments and markets in which we operate, often
holding a leadership or significant market share position.
The table below lists our reportable segments, including the product categories and brand composition within each segment.
Reportable Segments 	Product Categories (Sub-Categories) 	Major Brands
Beauty
Hair Care (Conditioners, Shampoos, Styling Aids, Treatments) 	Head & Shoulders, Herbal
Essences, Pantene, Rejoice
Personal Care (Antiperspirants and Deodorants, Personal Cleansing) 	Native, Old Spice, Safeguard,
Secret
Skin Care (Facial Moisturizers, Cleaners and Treatments) 	Olay, SK-II
Grooming Grooming (Appliances, Female Blades & Razors, Male Blades & Razors, Pre- and
Post-Shave Products, Other Grooming) 	Braun, Gillette, Venus
Health Care
Oral Care (Toothbrushes, Toothpastes, Other Oral Care) 	Crest, Oral-B
Personal Health Care (Gastrointestinal, Pain Relief, Rapid Diagnostics, Respiratory,
Vitamins/Minerals/Supplements, Other Personal Health Care)
Metamucil, Neurobion, Pepto-
Bismol, Vicks
Fabric & Home Care
Fabric Care (Fabric Enhancers, Laundry Additives, Laundry Detergents) 	Ariel, Downy, Gain, Tide
Home Care (Air Care, Dish Care, P&G Professional, Surface Care) Cascade, Dawn, Fairy, Febreze,
Mr. Clean, Swiffer
Baby, Feminine & Family Care
Baby Care (Baby Wipes, Taped Diapers and Pants) 	Luvs, Pampers
Feminine Care (Adult Incontinence, Menstrual Care) Always, Always Discreet,
Tampax
Family Care (Paper Towels, Tissues, Toilet Paper) 	Bounty, Charmin, Puffs
Effective July 1, 2024, the Beauty reportable business segment separated Skin and Personal Care into individual operating segments, Skin Care and Personal Care. This
transition included separation of the management team, strategic decision-making, innovation plans, financial targets, budgets and management reporting.
Throughout the MD&A, we reference business results by region, which are comprised of North America, Europe, Greater China, Latin America, Asia Pacific
and India, Middle East and Africa (IMEA).
The following table provides the percentage of net sales and net earnings by reportable business segment (excluding Corporate) for the three months ended
September 30, 2024:
Three Months Ended September 30, 2024
Net Sales 	Net Earnings
Beauty 	18 % 	17 %
Grooming 	8 % 	9 %
Health Care 	15 % 	16 %
Fabric & Home Care 	36 % 	35 %
Baby, Feminine & Family Care 	24 % 	23 %
Total Company 	100 % 	100 %
RECENT DEVELOPMENTS
Limited Market Portfolio Restructuring
In the fiscal year ended June 30, 2024, the Company started a limited market portfolio restructuring of its business operations, primarily in certain Enterprise
Markets, including Argentina and Nigeria, to address challenging macroeconomic and fiscal conditions. During the period ended September 30, 2024, the
Company completed this limited market portfolio restructuring with the substantial liquidation of its operations in Argentina and recorded incremental
restructuring charges of approximately $0.8 billion after tax, comprised primarily of non-cash charges for accumulated foreign currency translation losses
previously included in Accumulated other comprehensive income/(loss). The total incremental restructuring charges incurred under the program beginning in
the three-month period ended December 31, 2023, through the three-month period ended September 30, 2024, were approximately $1.2 billion after tax.
Consistent with our historical policies for ongoing restructuring-type activities, resulting charges were funded by and included within Corporate for segment
reporting. Restructuring charges above the normal ongoing level of restructuring costs are
(1)
(1)
(1)

-- 16 of 67 --

The Procter & Gamble Company 15
reported as non-core charges. For more details on the restructuring program, refer to Note 11 to the Consolidated Financial Statements.
SUMMARY OF RESULTS – Three Months Ended September 30, 2024
The following are highlights of results for the three months ended September 30, 2024, versus the three months ended September 30, 2023:
• Net sales decreased 1% to $21.7 billion versus the prior year period. Net sales increased 2% in Health Care, 1% in Fabric & Home Care and decreased 5%
in Beauty and 2% in Baby, Feminine & Family Care. Net sales in Grooming were unchanged. Organic sales, which exclude the impacts of acquisitions and
divestitures and foreign exchange, increased 2%. Organic sales increased 4% in Health Care, 3% in Grooming and Fabric & Home Care and decreased 2%
in Beauty. Organic sales in Baby, Feminine & Family Care were unchanged.
• Net earnings were $4.0 billion, a decrease of $569 million, or 12%, versus the prior year period due primarily to higher restructuring charges related to the
substantial liquidation of operations in certain Enterprise Markets, including Argentina.
• Net earnings attributable to Procter & Gamble were $4.0 billion, a decrease of $562 million, or 12%, versus the prior year period.
• Diluted EPS decreased 12% to $1.61 due to the decrease in net earnings. Core EPS, which excludes incremental restructuring charges, increased 5% to
$1.93.
• Operating cash flow was $4.3 billion. Adjusted free cash flow, which is defined as operating cash flow less capital expenditures and excluding payments
for the transitional tax resulting from the U.S. Tax Act, was $3.9 billion. Adjusted free cash flow productivity, which is defined as adjusted free cash flow
as a percentage of net earnings excluding a non-cash charge for accumulated foreign currency translation losses due to the substantial liquidation of
operations in Argentina, was 82%.
ECONOMIC CONDITIONS AND UNCERTAINTIES
Global Economic Conditions. Our products are sold in numerous countries worldwide, with more than half our sales generated outside the United States. Our
largest international markets are Greater China, the United Kingdom, Canada, Japan and Germany and collectively comprised approximately 20% of our net
sales in fiscal 2024. As a result, we are exposed to global macroeconomic factors, geopolitical tensions and government policies. We are exposed to market
risks from operating in challenging environments due to economic, political and social instabilities, natural disasters, debt and credit issues, currency controls,
foreign exchange and interest rate changes. These risks can negatively impact our net sales, net earnings and cash flows. For example, we are exposed to risks
due to the ongoing war between Russia and Ukraine. Our Russia business accounted for less than 2% of consolidated net sales and net earnings in the fiscal
year ended June 30, 2024 and less than 2% of net assets as of June 30, 2024.
Foreign Exchange. We have significant exposure to exchange rate fluctuations, both due to translation and transaction exposures. Translation exposures arise
from measuring income statements of foreign subsidiaries with functional currencies other than the U.S. dollar. Transaction exposures involve impacts from 1)
input costs that are denominated in currencies other than the local reporting currency and 2) revaluation of working capital balances denominated in currencies
other than the functional currency. We have experienced significant foreign exchange impacts in the past due to the weakening of certain foreign currencies
versus the US dollar, which have negatively impacted net sales, net earnings and cash flows. In response to the devaluation of foreign currencies (including
those deemed highly inflationary), any lags or inability (due to government restrictions) to implement price increases or the negative impacts of such actions on
product consumption may lead to a decline in our net sales, net earnings and cash flows.
Commodities and Supply Chain. Our costs are subject to fluctuations due to changes in commodity and input material prices, transportation costs,
inflationary impacts and productivity efforts. We have significant exposures to certain commodities and input materials, in particular certain oil-derived
materials like resins and paper-based materials like pulp. Volatility in the market price of commodities and input materials directly affects our costs.
Disruptions in manufacturing, supply and distribution operations can lead to increased costs. Legal or regulatory requirements and sustainability initiatives may
result in increased costs. We strive to implement, achieve and sustain cost improvement plans, including supply chain optimization and general overhead and
workforce optimization. Increased pricing in response to certain inflationary or cost increases may also offset portions of the cost impacts; however, such price
increases may negatively impact product consumption. If we are unable to manage cost impacts through pricing actions and consistent productivity
improvements, it may negatively impact our net sales, net earnings and cash flows.
Government Policies. We are exposed to changes in U.S. and foreign government legislative, regulatory or enforcement policies that can have a negative
impact on net sales, net earnings and cash flows. These include tax policy changes (both U.S. and foreign), including those resulting from the current work
being led by the OECD/G20 Inclusive Framework focused on "Addressing the Challenges of the Digitalization of the Economy”. Government controls such as
currency exchanges, pricing

-- 17 of 67 --

16 The Procter & Gamble Company
and import authorizations as well as government policies related to environmental and climate change matters and changes to international trade agreements
can also impact our financial performance.
For additional information on risk factors that could impact our business results, please refer to Risk Factors in Part I, Item 1A of the Company's Form 10-K for
the fiscal year ended June 30, 2024.
RESULTS OF OPERATIONS – Three Months Ended September 30, 2024
The following discussion provides a review of results for the three months ended September 30, 2024, versus the three months ended September 30, 2023.
Three Months Ended September 30
Amounts in millions, except per share amounts 	2024 	2023 	% Chg
Net sales 	$ 	21,737 $ 	21,871 	(1)%
Operating income 	5,797 	5,767 	1%
Earnings before income taxes 	5,140 	5,802 	(11)%
Net earnings 	3,987 	4,556 	(12)%
Net earnings attributable to Procter & Gamble 	3,959 	4,521 	(12)%
Diluted net earnings per common share 	1.61 	1.83 	(12)%
Core net earnings per common share 	1.93 	1.83 	5%
Three Months Ended September 30
COMPARISONS AS A PERCENTAGE OF NET SALES 	2024 	2023 	Basis Pt Chg
Gross margin 	52.1 % 	52.0 % 	10
Selling, general & administrative expense 	25.4 % 	25.6 % 	(20)
Operating income 	26.7 % 	26.4 % 	30
Earnings before income taxes 	23.6 % 	26.5 % 	(290)
Net earnings 	18.3 % 	20.8 % 	(250)
Net earnings attributable to Procter & Gamble 	18.2 % 	20.7 % 	(250)
Net Sales
Net sales for the quarter decreased 1% to $21.7 billion as increased pricing of 1% was more than fully offset by unfavorable foreign exchange of 1% and
rounding impacts. Unit volume and mix had a neutral impact on net sales. Excluding the impact of acquisitions and divestitures and foreign exchange, organic
sales increased 2% and organic volume increased 1%.
The following table summarizes key drivers of the change in net sales by reportable segment:
Net Sales Change Drivers 2024 vs. 2023 (Three Months Ended September 30)
Volume with
Acquisitions &
Divestitures
Volume Excluding
Acquisitions &
Divestitures
Foreign
Exchange 	Price 	Mix 	Other
Net Sales
Growth
Beauty 	(2) % 	— % 	(1) % 	1 % 	(3) % 	— % 	(5) %
Grooming 	4 % 	5 % 	(2) % 	1 % 	(3) % 	— % 	— %
Health Care 	(1) % 	(1) % 	(1) % 	1 % 	4 % 	(1) % 	2 %
Fabric & Home Care 	1 % 	1 % 	(1) % 	— % 	1 % 	— % 	1 %
Baby, Feminine & Family Care 	(1) % 	(1) % 	(1) % 	— % 	— % 	— % 	(2) %
Total Company 	— % 	1 % 	(1)% 	1 % 	— % 	(1)% 	(1)%
Net sales percentage changes are approximations based on quantitative formulas that are consistently applied.
Other includes the sales mix impact from acquisitions and divestitures and rounding impacts necessary to reconcile volume to net sales.
Operating Costs
Gross margin increased 10 basis points to 52.1% of net sales for the quarter. The increase in gross margin was due to:
• 170 basis points of manufacturing productivity savings and
• 30 basis points of increase due to higher pricing.
These impacts were partially offset by:
(1)
(2)
(1)
(2)

-- 18 of 67 --

The Procter & Gamble Company 17
• 90 basis points of higher commodity costs,
• 60 basis points of decline from unfavorable product mix including the decline of the super-premium SK-II brand and
• 40 basis points of product and packaging investments.
Total SG&A spending decreased 2% to $5.5 billion versus the prior year period due to a decrease in other operating expenses. SG&A as a percentage of net
sales decreased 20 basis points to 25.4% due to a decrease in other operating expenses, partially offset by an increase in marketing spending as a percentage of
net sales. Marketing spending as a percentage of net sales increased 40 basis points as the increase in marketing spending was partially offset by productivity
savings. Overhead costs as a percentage of net sales was unchanged as increased productivity savings were offset by an increase in overhead spending and
foreign exchange impacts. Other operating expenses as a percentage of net sales decreased 60 basis points due primarily to higher foreign exchange
transactional charges in the prior year period. Productivity-driven cost savings delivered 60 basis points of benefit to SG&A as a percentage of net sales.
Operating margin increased 30 basis points to 26.7% due to the increase in gross margin and the decrease in SG&A as a percentage of net sales, as discussed
above. Operating income increased $30 million, or 1%, to $5.8 billion for the quarter as the decrease in net sales was more than offset by the increase in
operating margin, the components of which are discussed above.
Non-Operating Expenses and Income
Interest expense was $238 million for the quarter, an increase of $13 million versus the prior year period. Interest income was $135 million for the quarter, an
increase of $7 million versus the prior year period. Other non-operating income/(expense) was $(554) million, which is a decrease of $686 million versus the
prior year period due primarily to a non-cash charge for accumulated foreign currency translation losses due to the substantial liquidation of operations in
Argentina.
Income Taxes
The effective income tax rate for the three months ended September 30, 2024, was 22.4%, compared to 21.5% for the three months ended September 30, 2023.
The increase in the effective tax rate was driven by a 300 basis-point increase due primarily to the charge for accumulated foreign currency translation losses
due to the substantial liquidation of operations in Argentina, partially offset by a 160 basis-point decrease due to higher excess tax benefits of share-based
compensation and a decrease driven by favorable geographic mix impacts.
Net Earnings
Net earnings decreased $569 million, or 12%, to $4.0 billion due primarily to the decrease in other non-operating income/(expense) discussed above. Foreign
exchange had a positive impact of approximately $61 million on net earnings for the quarter, including both transactional and translational impacts from
converting earnings from foreign subsidiaries to U.S. dollars. Net earnings attributable to Procter & Gamble decreased $562 million, or 12%, to $4.0 billion for
the quarter. Diluted EPS decreased 12% to $1.61 versus the prior year period due to the decrease in net earnings.
SEGMENT RESULTS – Three Months Ended September 30, 2024
The following discussion provides a review of results by reportable business segment. Analysis of the results for the three months ended September 30, 2024, is
provided based on a comparison to the three months ended September 30, 2023. The primary financial measures used to evaluate segment performance are net
sales and net earnings. The table below provides supplemental information on net sales, earnings before income taxes and net earnings by reportable business
segment for the three months ended September 30, 2024, versus the comparable prior year period (dollar amounts in millions):
Three Months Ended September 30, 2024
Net Sales
% Change
Versus Year Ago
Earnings/(Loss) Before
Income Taxes
% Change
Versus Year Ago 	Net Earnings/(Loss)
% Change
Versus Year Ago
Beauty 	$ 	3,892 	(5) % $ 	1,067 	(15) % $ 	840 	(13) %
Grooming 	1,723 	— % 	522 	(2) % 	426 	1 %
Health Care 	3,147 	2 % 	953 	7 % 	741 	8 %
Fabric & Home Care 	7,710 	1 % 	2,077 	2 % 	1,621 	3 %
Baby, Feminine & Family Care 	5,102 	(2) % 	1,383 	(2) % 	1,066 	(1) %
Corporate 	163 	N/A 	(862) 	N/A 	(707) 	N/A
Total Company 	$ 	21,737 	(1)% $ 	5,140 	(11)% $ 	3,987 	(12)%
Beauty
Three months ended September 30, 2024, compared with three months ended September 30, 2023
Beauty net sales decreased 5% to $3.9 billion as negative impacts of unfavorable mix of 3% (due primarily to the decline of the

-- 19 of 67 --

18 The Procter & Gamble Company
super-premium SK-II brand, which has higher than segment-average selling prices), a 2% decrease in unit volume and unfavorable foreign exchange of 1%
were partially offset by positive impacts of higher pricing of 1%. Excluding the impact of acquisitions and divestitures and foreign exchange, organic sales
decreased 2% and organic volume was unchanged. Global market share of the Beauty segment increased 0.3 points.
• Hair Care net sales decreased low single digits. Negative impacts of divestitures, unfavorable foreign exchange and a unit volume decrease were partially
offset by positive impacts of favorable geographic and brand mix (due to growth of the premium Native brand) and higher pricing (driven by Europe and
Latin America). The volume decrease was driven by a decline in Greater China (due to a more prominent market contraction in the retail channel where we
have higher shares), partially offset by growth in North America (due to market growth) and Asia Pacific (due to increased marketing activity). Organic
sales increased low single digits driven by double-digit growth in Latin America and a high single-digit growth in North America, partially offset by a
double-digit decline in Greater China. Global market share of the Hair Care category decreased 0.6 points.
• Personal Care net sales increased high single digits. Positive impacts of an increase in unit volume, favorable product mix and higher pricing (primarily in
North America) were partially offset by unfavorable foreign exchange. The volume increase was driven by growth in North America (due to innovation)
and Europe (due to distribution expansion and innovation), partially offset by a decline in Greater China (due to market contraction). Organic sales
increased high single digits due to a double-digit growth in North America, partially offset by a high single-digit decline in Greater China. Global market
share of the Personal Care category increased 0.4 points.
• Skin Care net sales decreased more than 20%. Negative impacts of a decrease in unit volume and unfavorable mix (due primarily to the decline of the
super-premium SK-II brand, which has higher than category-average selling prices), were partially offset by higher pricing primarily in Greater China. The
volume decrease was driven by declines in all regions, led by Greater China (due primarily to the decline of the super-premium SK-II brand and market
contraction) and North America (due to distribution losses). Organic sales decreased more than 20% due to a more than 30% decline in Asia Pacific and a
more than 20% declines in Greater China and North America. Global market share of the Skin Care category decreased 0.4 points.
Net earnings decreased 13% to $840 million due to the decrease in net sales and a 210 basis-point decline in net earnings margin. Net earnings margin
decreased due to a decrease in gross margin and an increase in SG&A as a percentage of net sales partially offset by a lower effective tax rate. The gross
margin decline was driven by negative product mix (due to the decline of the super-premium SK-II brand) partially offset by increased productivity savings.
SG&A as a percentage of net sales increased due primarily to the negative scale effects of the net sales decrease, partially offset by higher foreign exchange
transactional charges in the prior year period. The lower effective tax rate was driven by favorable geographic mix.
Grooming
Three months ended September 30, 2024, compared with three months ended September 30, 2023
Grooming net sales were unchanged at $1.7 billion as the benefits of a 4% increase in unit volume and higher pricing of 1% (driven primarily by IMEA and
Asia Pacific) were partially offset by unfavorable geographic mix of 3% and unfavorable foreign exchange of 2%. The volume increase was driven by growth
in IMEA (due to increased distribution) and Europe (due to market growth). Excluding the impact of acquisitions and divestitures and foreign exchange,
organic sales increased 3% driven by a more than 20% growth in IMEA and a low single-digit growth in Europe, partially offset by a high single-digit decline
in Greater China. Excluding the impact of acquisitions and divestitures, organic volume increased 5%. Global market share of the Grooming segment increased
0.9 points.
Net earnings increased 1% to $426 million due to a 30 basis-point increase in net earnings margin. Net earnings margin increased as a decrease in SG&A as a
percentage of net sales and a lower effective tax rate were partially offset by a decrease in gross margin. The gross margin decrease was primarily driven by
unfavorable geographic mix. SG&A as a percentage of net sales decreased due primarily to higher foreign exchange transactional charges in the prior year
period. The lower effective tax rate was driven by favorable geographic mix.
Health Care
Three months ended September 30, 2024, compared with three months ended September 30, 2023
Health Care net sales increased 2% to $3.1 billion driven by favorable product mix of 4% and higher pricing of 1%, partially offset by a 1% decrease in unit
volume and unfavorable foreign exchange of 1%. Excluding the impact of acquisitions and divestitures and foreign exchange, organic sales increased 4%.
Global market share of the Health Care segment increased 0.1 points.
• Oral Care net sales increased low single digits driven by the positive impacts of favorable product mix (due to growth of power brushes and premium
paste, which have higher than category-average selling prices) partially offset by a decline in unit volume and unfavorable foreign exchange. The volume
decrease was driven by declines in Greater China (due to market contraction and share losses) and IMEA (due to exit of operations in certain enterprise
markets), partially offset by growth in North America (due to market growth and innovation). Organic sales increased low single digits driven by a high

-- 20 of 67 --

The Procter & Gamble Company 19
single-digit increase in Europe and a mid-single-digit increase in North America, partially offset by a high-teens decrease in Greater China. Global market
share of the Oral Care category increased 0.5 points.
• Personal Health Care net sales increased low single digits as the positive impacts of favorable product mix (due to the growth of respiratory products,
which have higher than category-average selling prices) and higher pricing (driven by Latin America and Asia Pacific) were partially offset by unfavorable
foreign exchange. Unit volume was unchanged as growth in North America (due to innovation and distribution gains) was offset by declines primarily in
IMEA (due to increased competitive activity). Organic sales increased mid-single digits driven by a double-digit growth in Latin America and a high
single-digit growth in North America, partially offset by a mid-single-digit decline in IMEA. Global market share of the Personal Health Care category
decreased 0.1 points.
Net earnings increased 8% to $741 million due to the net sales growth and a 110 basis-point increase in net earnings margin. Net earnings margin increased due
to an increase in gross margin and a decrease in SG&A as a percentage of net sales. The gross margin increase was driven primarily by favorable product mix
(due to the growth in respiratory products, which have higher than segment-average gross margins). SG&A as a percentage of net sales decreased due to lower
marketing spending and the positive scale impacts of the net sales increase.
Fabric & Home Care
Three months ended September 30, 2024, compared with three months ended September 30, 2023
Fabric & Home Care net sales increased 1% to $7.7 billion driven by a unit volume increase of 1% and favorable mix of 1%, partially offset by unfavorable
foreign exchange of 1%. Excluding the impact of foreign exchange and acquisitions and divestitures, organic sales increased 3%. Global market share of the
Fabric & Home Care segment increased 0.1 points.
• Fabric Care net sales were unchanged as the positive impact of favorable geographic mix was offset by unfavorable foreign exchange. Volume was
unchanged as growth in North America (due to innovation) and Europe (due to increased marketing support) was fully offset by declines in Latin America
(due to the substantial liquidation of operations in Argentina) and Asia Pacific (due to increased pricing). Organic sales increased low single digits driven
by a high single-digit growth in Europe and a mid-single-digit growth in North America, partially offset by a low teens decline in IMEA and a double-digit
decline in Latin America. Global market share of the Fabric Care category decreased 0.2 points.
• Home Care net sales increased low single digits. Positive impacts of favorable premium product mix and an increase in unit volume were partially offset
by the negative impacts of unfavorable foreign exchange and divestitures. The increase in unit volume was due primarily to growth in North America (due
to market growth) and Europe (due to distribution gains), partially offset by a decline in Latin America (due to the substantial liquidation of operations in
Argentina). Organic sales increased mid-single digits driven by a high single-digit growth in Europe and mid-single-digit growth in North America. Global
market share of the Home Care category increased 0.6 points.
Net earnings increased 3% to $1.6 billion due to the increase in net sales and a 50 basis-point improvement in net earnings margin. Net earnings margin
increased due to an increase in gross margin partially offset by an increase in SG&A as a percentage of net sales. The gross margin increase was driven by
increased productivity savings, partially offset by unfavorable foreign exchange and unfavorable mix due to the growth of premium products that have lower
than segment-average gross margins. SG&A as a percentage of net sales increased due to an increase in marketing spending, partially offset by higher foreign
exchange transactional charges in the prior year period.
Baby, Feminine & Family Care
Three months ended September 30, 2024, compared with three months ended September 30, 2023
Baby, Feminine & Family Care net sales decreased 2% to $5.1 billion due to a 1% decrease in unit volume and unfavorable foreign exchange of 1%. Excluding
the impacts of foreign exchange and acquisitions and divestitures, organic sales were unchanged. Global market share of the Baby, Feminine & Family Care
segment decreased 0.3 points.
• Baby Care net sales decreased high single digits. Negative impacts of a decrease in unit volume, unfavorable foreign exchange and divestitures were
partially offset by favorable geographic and product mix (due to a higher proportion of premium diapers, which have higher than category-average selling
prices). The unit volume decline was driven across most regions led by IMEA (due to share losses), Latin America (due to the substantial liquidation of
operations in Argentina) and Europe (due to share losses). Organic sales decreased mid-single digits due to a mid-teens decline in IMEA and high single-
digit decline in Europe, partially offset by a high single-digit growth in Greater China. Global market share of the Baby Care category decreased 0.3
points.
• Feminine Care net sales were unchanged. Positive impacts of favorable geographic mix and higher pricing (driven primarily by North America and IMEA)
were partially offset by a decrease in unit volume and unfavorable foreign exchange. The volume decrease was primarily driven by declines in Greater
China (due to share losses) and Europe (due to increased pricing), partially offset by growth in North America (due to market growth). Organic sales
increased low single digits driven by a low single-digit growth in North America partially offset by a mid-single-digit decline in Greater China. Global
market share of the Feminine Care category decreased 0.5 points.

-- 21 of 67 --

20 The Procter & Gamble Company
• Net sales in Family Care, which is predominantly a North America business, increased low single digits driven by an increase in unit volume, partially
offset by lower pricing (due to increased promotional spending). Organic sales increased mid-single digits. North America market share of the Family Care
category was unchanged.
Net earnings decreased 1% to $1.1 billion as the decrease in net sales was partially offset by a 20 basis-point increase in net earnings margin. Net earnings
margin increased primarily due to a slight increase in gross margin and a lower effective tax rate. Gross margin increased primarily due to increased
productivity savings partially offset by higher commodity costs. SG&A as a percentage of net sales was unchanged as an increase in overhead spending was
offset by higher foreign exchange transactional charges in the prior year period. The lower effective tax rate was driven by favorable geographic mix.
Corporate
Corporate includes certain operating and non-operating activities not allocated to specific business segments. These include but are not limited to incidental
businesses managed at the corporate level, gains and losses related to certain divested brands or businesses, impacts from various financing and investing
activities, impacts related to employee benefits, asset impairments and restructuring activities including manufacturing and workforce optimization. Corporate
also includes reconciling items to adjust the accounting policies used within the reportable segments to U.S. GAAP. The most notable ongoing reconciling item
is income taxes, which adjusts the blended statutory rates that are reflected in the reportable segments to the overall Company effective tax rate.
For the three months ended September 30, 2024, Corporate net sales increased $19 million to $163 million due to an increase in net sales of incidental
businesses managed at the corporate level. Corporate net earnings decreased $539 million to a loss of $707 million for the quarter due primarily to incremental
restructuring charges.
LIQUIDITY & CAPITAL RESOURCES
Operating Activities
Operating cash flow was $4.3 billion fiscal year to date, a decrease of $602 million versus the prior year period. Net earnings, adjusted for non-cash items
(depreciation and amortization, share-based compensation expense, deferred income taxes and gain/loss on sale of assets), generated $5.8 billion of operating
cash flow. Working capital and other impacts used $1.5 billion of cash in the period primarily driven by the payment of prior fiscal year-end incentive
compensation accruals, reduction in postretirement benefit accruals and current portion of the transitional tax payments related to the U.S. Tax Act. Days sales
outstanding were flat and Days inventory on hand increased one day.
Investing Activities
Investing activities used $1.1 billion of cash fiscal year to date primarily driven by capital expenditures and the settlement of net investment hedges.
Financing Activities
Financing activities used $0.6 billion of net cash fiscal year to date, mainly due to dividends to shareholders and treasury stock purchases, partially offset by a
net debt increase and the impact of stock options and other.
As of September 30, 2024, our current liabilities exceeded current assets by $9.0 billion. We anticipate being able to support our short-term liquidity and
operating needs largely through cash generated from operations. We have strong short- and long-term debt ratings that have enabled and should continue to
enable us to refinance our debt as it becomes due at favorable rates in commercial paper and bond markets. In addition, we have agreements with a diverse
group of financial institutions that, if needed, should provide sufficient funding to meet short-term financing requirements.
MEASURES NOT DEFINED BY U.S. GAAP
In accordance with the SEC's Regulation S-K Item 10(e), the following provides definitions of the non-GAAP measures and the reconciliation to the most
closely related GAAP measure. We believe that these measures provide useful perspective on underlying business trends (i.e., trends excluding non-recurring
or unusual items) and results and provide a supplemental measure of period-to-period results. The non-GAAP measures described below are used by
management in making operating decisions, allocating financial resources and for business strategy purposes. These measures may be useful to investors, as
they provide supplemental information about business performance and provide investors a view of our business results through the eyes of management.
These measures are also used to evaluate senior management and are a factor in determining their at-risk compensation. These non-GAAP measures are not
intended to be considered by the user in place of the related GAAP measures but rather as supplemental information to our business results. These non-GAAP
measures may not be the same as similar measures used by other companies due to possible differences in method and in the items or events being adjusted.
Organic sales growth. Organic sales growth is a non-GAAP measure of sales growth excluding the impacts of acquisitions and divestitures and foreign
exchange from year-over-year comparisons. We believe this measure provides investors with a supplemental understanding of underlying sales trends by
providing sales growth on a consistent basis. This measure is used in assessing the achievement of management goals for at-risk compensation.

-- 22 of 67 --

The Procter & Gamble Company 21
The following table provides a numerical reconciliation of organic sales growth to reported net sales growth:
Three Months Ended September 30, 2024 	Net Sales Growth 	Foreign Exchange Impact
Acquisition & Divestiture
Impact/Other 	Organic Sales Growth
Beauty 	(5) % 	1 % 	2 % 	(2) %
Grooming 	— % 	2 % 	1 % 	3 %
Health Care 	2 % 	1 % 	1 % 	4 %
Fabric & Home Care 	1 % 	1 % 	1 % 	3 %
Baby, Feminine & Family Care 	(2) % 	1 % 	1 % 	— %
Total Company 	(1)% 	1 % 	2 % 	2 %
Acquisition & Divestiture Impact/Other includes the volume and mix impact of acquisitions and divestitures and rounding impacts necessary to reconcile net sales to
organic sales.
Adjusted free cash flow. Adjusted free cash flow is defined as operating cash flow less capital expenditures and excluding payments for the transitional tax
resulting from the U.S. Tax Act. Adjusted free cash flow represents the cash that the Company is able to generate after taking into account planned maintenance
and asset expansion. We view adjusted free cash flow as an important measure because it is one factor used in determining the amount of cash available for
dividends, share repurchases, acquisitions and other discretionary investments.
The following table provides a numerical reconciliation of adjusted free cash flow ($ millions):
Three Months Ended September 30, 2024
Operating Cash Flow 	Capital Spending 	U.S. Tax Act Payments 	Adjusted Free Cash Flow
$ 	4,302 $ 	(993) $ 	562 $ 	3,871
Adjusted free cash flow productivity. Adjusted free cash flow productivity is defined as the ratio of adjusted free cash flow to net earnings excluding a non-
cash charge for accumulated foreign currency translation losses due to the substantial liquidation of operations in Argentina. We view adjusted free cash flow
productivity as a useful measure to help investors understand P&G’s ability to generate cash. Adjusted free cash flow productivity is used by management in
making operating decisions, in allocating financial resources and for budget planning purposes. This measure is also used in assessing the achievement of
management goals for at-risk compensation.
The following table provides a numerical reconciliation of adjusted free cash flow productivity ($ millions):
Three Months Ended September 30, 2024
Adjusted Free Cash Flow 	Net Earnings
Adjustments to
Net Earnings
Net Earnings
as Adjusted
Adjusted Free Cash
Flow Productivity
$ 	3,871 $ 	3,987 $ 	752 $ 	4,739 	82 %
Adjustments to Net earnings relate to a non-cash charge for accumulated foreign currency translation losses due to the substantial liquidation of operations in Argentina.
(1)
(1)
(1)
(1)

-- 23 of 67 --

22 The Procter & Gamble Company
Core EPS. Core EPS is a measure of the Company's diluted EPS excluding items that are not judged by management to be part of the Company's sustainable
results or trends. Management views this non-GAAP measure as a useful supplemental measure of Company performance over time. This measure is also used
in assessing the achievement of management goals for at-risk compensation. The Core earnings measures included in the following reconciliation tables refer
to the equivalent GAAP measures adjusted as applicable for the following items:
• Incremental restructuring: The Company has historically had an ongoing level of restructuring activities of approximately $250 - $500 million before
tax. In the fiscal year ended June 30, 2024, the Company started a limited market portfolio restructuring of its business operations, primarily in certain
Enterprise Markets, including Argentina and Nigeria, to address challenging macroeconomic and fiscal conditions. During the period ended
September 30, 2024, the Company completed this limited market portfolio restructuring with the substantial liquidation of its operations in Argentina.
The adjustment to Core earnings includes the restructuring charges that exceed the normal, recurring level of restructuring charges.
We do not view the above items to be part of our sustainable results, and their exclusion from core earnings measures provides a more comparable measure of
year-on-year results. These items are also excluded when evaluating senior management in determining their at-risk compensation.
THE PROCTER & GAMBLE COMPANY AND SUBSIDIARIES
Reconciliation of Non-GAAP Measures
Three Months Ended September 30, 2024 	Three Months Ended
September 30, 2023
Amounts in millions except per share amounts 	As Reported (GAAP) 	Incremental Restructuring
Core
(Non-GAAP)
As Reported
(GAAP)
Cost of products sold 	$ 	10,421 	$ 	20 $ 	10,441 $ 	10,501
Selling, general and administrative expense 	5,519 	(25) 	5,494 	5,604
Operating income 	5,797 	5 	5,802 	5,767
Other non-operating income/(expense), net 	(554) 	789 	235 	132
Income taxes 	1,152 	(7) 	1,145 	1,246
Net earnings attributable to P&G 	3,959 	801 	4,761 	4,521
Core EPS
Diluted net earnings per common share 	$ 	1.61 	$ 	0.32 	$ 	1.93 $ 	1.83
For the three months ended September 30, 2023, there were no adjustments to or reconciling items for Core EPS.
Diluted net earnings per common share are calculated on Net earnings attributable to Procter & Gamble.
CHANGE VERSUS YEAR AGO
Net earnings attributable to P&G 	(12)%
Core net earnings attributable to P&G 	5 %
Diluted net earnings per common share 	(12)%
Core EPS 	5 %
Item 3. 	Quantitative and Qualitative Disclosures About Market Risk
There have been no material changes in the Company’s exposure to market risk since June 30, 2024. Additional information can be found in Note 9, Risk
Management Activities and Fair Value Measurements, of the Company's Form 10-K for the fiscal year ended June 30, 2024.
Item 4. 	Controls and Procedures
Evaluation of Disclosure Controls and Procedures
The Company’s Chairman of the Board, President and Chief Executive Officer, Jon R. Moeller, and the Company’s Chief Financial Officer, Andre Schulten,
performed an evaluation of the Company’s disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of
1934 (Exchange Act)) as of the end of the period covered by this report.
Messrs. Moeller and Schulten have concluded that the Company’s disclosure controls and procedures were effective to ensure that information required to be
disclosed in reports we file or submit under the Exchange Act is (1) recorded, processed, summarized and reported within the time periods specified in SEC
rules and forms, and (2) accumulated and communicated to our management, including Messrs. Moeller and Schulten, to allow their timely decisions regarding
required disclosure.
(1)
(2)
(1)
(2)

-- 24 of 67 --

The Procter & Gamble Company 23
Changes in Internal Control Over Financial Reporting
There were no changes in our internal control over financial reporting that occurred during the Company’s fiscal quarter ended September 30, 2024, that have
materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.
PART II. OTHER INFORMATION
Item 1. 	Legal Proceedings
The Company is subject, from time to time, to certain legal proceedings and claims arising out of our business, which cover a wide range of matters, including
antitrust and trade regulation, product liability, advertising, contracts, environmental issues, patent and trademark matters, labor and employment matters and
tax. In addition, SEC regulations require that we disclose certain environmental proceedings arising under Federal, State or local law when a governmental
authority is a party and such proceeding involves potential monetary sanctions that the Company reasonably believes will exceed a certain threshold ($1
million or more).
There were no material changes during the quarter ended September 30, 2024, to our disclosure in Part I, Item 3, “Legal Proceedings” of our Form 10-K for the
fiscal year ended June 30, 2024. There were no relevant matters to disclose under this Item for this period.

-- 25 of 67 --

24 The Procter & Gamble Company
Item 1A. 	Risk Factors
For information on risk factors, please refer to "Risk Factors" in Part I, Item 1A of the Company's Form 10-K for the fiscal year ended June 30, 2024.
Item 2. 	Unregistered Sales of Equity Securities, Use of Proceeds and Issuer Purchases of Equity Securities
ISSUER PURCHASES OF EQUITY SECURITIES
Period
Total Number of
Shares Purchased
Average Price Paid per
Share
Total Number of Shares Purchased as Part
of Publicly Announced Plans or Programs
Approximate Dollar Value of Shares That May
Yet Be Purchased Under Our Share Repurchase
Program
7/01/2024 - 7/31/2024 	7,354,034 	$166.84 	5,232,113
8/01/2024 - 8/31/2024 	6,320,000 	168.32 	6,320,000
9/01/2024 - 9/30/2024 	— 	— 	—
Total 	13,674,034 	$167.52 	11,552,113 	(3)
All transactions are reported on a trade date basis and were made in the open market with large financial institutions. This table excludes shares withheld from employees to
satisfy tax withholding requirements on option exercises and other equity-based transactions. The Company administers cashless exercises through an independent third
party and does not repurchase stock in connection with cashless exercises.
Average price paid per share for open market transactions excludes commission.
In accordance with the repurchase program announced on July 30, 2024, the Company reaffirmed in its earnings release on October 18, 2024, that it expects to reduce
outstanding shares through direct share repurchases at a value of $6 to $7 billion in fiscal year 2025, notwithstanding any purchases under the Company's compensation and
benefit plans. Purchases may be made in the open market and/or private transactions and purchases may be increased, decreased or discontinued at any time without prior
notice. The share repurchases are authorized pursuant to a resolution issued by the Company's Board of Directors and are expected to be financed by a combination of
operating cash flows and issuance of debt.
Item 5. 	Other Information
During the three months ended September 30, 2024, none of our directors or officers adopted or terminated a "Rule 10b5-1 trading arrangement" or "non-Rule
10b5-1 trading arrangement" as defined in Item 408 of Regulation S-K.
(1) 	(2) 	(3)
(3)
(3)
(3)
(1)
(2)
(3)

-- 26 of 67 --

The Procter & Gamble Company 25
Item 6. 	Exhibits
3.1 Amended Articles of Incorporation (as amended by shareholders at the annual meeting on October 11, 2011 and consolidated by the
Board of Directors on April 8, 2016) (Incorporated by reference to Exhibit (3-1) of the Company's Form 10-K for the year ended June
30, 2016)
3.2 Regulations (as approved by the Board of Directors on December 13, 2022, pursuant to authority granted by shareholders at the annual
meeting on October 13, 2009) (Incorporated by reference to Exhibit (3-2) of the Company’s Current Report on Form 8-K filed
December 13, 2022)
10.1 Company's Form of Separation Agreement & Release *+
10.2 The Procter & Gamble Performance Stock Program Summary *+
10.3 Performance Stock Program related correspondence and terms and conditions *+
10.4 Long-Term Incentive Program related correspondence and terms and conditions *+
31.1 Rule 13a-14(a)/15d-14(a) Certification – Chief Executive Officer +
31.2 Rule 13a-14(a)/15d-14(a) Certification – Chief Financial Officer +
32.1 Section 1350 Certifications – Chief Executive Officer +
32.2 Section 1350 Certifications – Chief Financial Officer +
101.SCH 	Inline XBRL Taxonomy Extension Schema Document
101.CAL 	Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF 	Inline XBRL Taxonomy Definition Linkbase Document
101.LAB 	Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE 	Inline XBRL Taxonomy Extension Presentation Linkbase Document
104 Cover Page Interactive Data File (formatted in Inline XBRL and contained in Exhibit 101)
* Compensatory plan or arrangement
+ Filed herewith
Pursuant to Rule 406T of Regulation S-T, this information is furnished and not filed for purposes of Sections 11 or 12 of the Securities Act of 1933 and
Section 18 of the Securities Exchange Act of 1934, and otherwise is not subject to liability under these sections.
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned
thereunto duly authorized.
THE PROCTER & GAMBLE COMPANY
October 18, 2024 	/s/ MATTHEW W. JANZARUK
Date 	(Matthew W. Janzaruk)
Senior Vice President - Chief Accounting Officer
(Principal Accounting Officer)
(1)
(1)
(1)
(1)
(1)
(1)

-- 27 of 67 --

Exhibit (10.1)
Company’s Form of Separation Agreement & Release

-- 28 of 67 --

SEPARATION AGREEMENT & RELEASE
To: «Employee_Name»
Date: «Actual_Offer_Date»
«Company» (“P&G”) is willing to provide you with certain assistance following your employment separation from the Company. The following,
which is subject to your approval, sets forth our proposed agreement to do so. Your receipt of the benefits described below is conditioned upon
your accepting, and abiding by, the terms of this Agreement.
Employment Separation Date: 	Your Employment Separation Date will be «Exit_Date», referred to as your “Employment Separation
Date.” You understand and agree that if P&G determines that you engaged in misconduct during your
employment, or if you fail to perform your work and responsibilities in a satisfactory manner up to and
including your Employment Separation Date, P&G may terminate your employment immediately and
will not provide, nor be obligated to provide, the payment(s) and other benefits described in this
Agreement. Otherwise, unless noted below, your pay and benefits will cease as of your Employment
Separation Date.
Separation Payment: 	As soon as administratively practical after your Employment Separation Date, P&G will provide you
with a Separation Payment of $«Total_Amount», less legally required withholdings and deductions. In
no event will payment be made before expiration of the seven-day revocation period discussed below or
later than the March 15th of the year following the year which includes your Employment Separation
Date. The Separation Payment will be the only monetary assistance P&G provides upon your
separation. Other resources may be available to you as a participant in general compensation and
benefit plans, which it will be your responsibility to identify and make any necessary arrangements
upon separation.
Amounts you owe to P&G as of your Employment Separation Date, including, but not limited to, wage
and/or benefit overpayments and unpaid loans, will also be deducted from the Separation Payment.

-- 29 of 67 --

Payment for Unvested PST: 	If you are not fully-vested in the Procter & Gamble Profit Sharing Trust and Employee Stock
Ownership Plan (“PST”) as of your Employment Separation Date, as soon as administratively practical
after your Employment Separation Date, but no later than the March 15 of the year following the year
which includes your Employment Separation Date, you will receive a lump sum payment in an amount
substantially equivalent to the non-vested credits in your account in the PST.
STAR Awards: 	As of your Employment Separation Date, if you were otherwise eligible for a STAR award and you
worked at least 28 days (4 calendar weeks) during that fiscal year, you will receive a pro-rated STAR
award for that fiscal year. Your STAR award will be pro-rated by dividing the number of calendar days
during the fiscal year from July 1 through your Employment Separation Date by 365. However, if you
are on a leave of absence prior to your Employment Separation Date, your first day out of the office will
be used to calculate the pro-rated percent.
Your STAR award will be paid in cash in the September (but no later than September 15th) immediately
following the end of the fiscal year in which you terminate. Any current election for Stock Options will
be reverted to cash.
Equity Awards: 	Your separation will be treated as a Special Separation for purposes of any outstanding equity awards
granted under the Procter & Gamble 2009 Stock and Incentive Compensation Plan or the Gillette
Company 2004 Long-Term Incentive Plan and, as a result, you will retain the awards subject to the
original terms and conditions of the awards. You will also retain awards granted under the Procter &
Gamble 2014 Stock & Incentive Compensation Plan and the Procter & Gamble 2019 Stock & Incentive
Compensation Plan subject to the terms and conditions of those Awards. For any award granted under
the Long-Term Incentive Program (LTIP) and/or Performance Stock Program (PSP) within one year
prior to the separation date, that award will be prorated based on the number of days worked in the 12
months following the October grant date, with a minimum of 28 days worked beyond the October grant
date.
This Separation Letter & Release does not alter the rights and obligations that you may have under the
Procter & Gamble 2019 Stock & Incentive Compensation Plan, the Procter & Gamble 2014 Stock &
Incentive Compensation Plan, the Procter & Gamble 2009 Stock and Incentive Compensation Plan, and
the Gillette Company 2004 Long-Term Incentive Plan.
th

-- 30 of 67 --

Current Health, Dental, and Life
Insurance Benefits:
If you are enrolled in P&G’s active health (including medical, prescription drug, and EAP coverage),
active dental, and company-paid life insurance coverage, that coverage will continue under the same
terms until «Benefits_End_Date».
If you continue to receive P&G active health coverage during the extension of benefits period, that
coverage will be impacted if you (or your eligible dependents, including but not limited to your spouse
or domestic partner) are or become eligible for Medicare. For more information on this impact, see the
Coordination with Medicare section in the Summary Plan Description for your P&G active health
coverage.
If you continue to receive P&G active health coverage during the extension of benefits period, you may
be entitled to continue your health and dental coverage under COBRA when the extension of benefits
period ends. If you are entitled to COBRA continuation coverage, you will receive a notice of your
right to elect COBRA.

-- 31 of 67 --

Retiree Medical and Dental Benefits: If you were eligible for P&G retiree healthcare coverage on your Employment Separation Date, you
will be eligible to enroll in P&G’s retiree medical and dental insurance coverage. You are eligible for
P&G retiree healthcare coverage if you satisfy the regular retiree eligibility rules (i.e., you are a
Regular Retiree) as of your Employment Separation Date. Under the terms of this Agreement, you also
are eligible for P&G retiree healthcare coverage as a Special Retiree by satisfying the Rule of 70 as of
your Employment Separation Date. You satisfy the Rule of 70 when your full years of age plus your
full years of service equal 70. If you are eligible for P&G’s retiree healthcare coverage as either a
Regular Retiree or a Special Retiree as of your Employment Separation Date, you should contact P&G
Benefits Services before your extension of coverage ends to request retiree healthcare enrollment
information. For details regarding the terms and conditions of your retiree health coverage, please refer
to and review the summary plan descriptions, available at the P&G Benefits website.
Important Note: If you become employed by a direct competitor of P&G (as determined by P&G’s
Chief Human Resources Officer) in an officer and/or director capacity, you will not be eligible for
coverage under P&G’s retiree healthcare coverage as long as you remain employed by such competitor.
If you have questions, please contact P&G Benefits Services at 1-844-786-6588.
Outplacement Services: 	P&G’s preferred third-party provider will provide services to assist you in managing your transition to
a new future, based on your interest. Services include pre-decision counseling, career transition
programs, and job development opportunities. P&G’s preferred third-party provider will also assist you
in preparing for your job search, including résumé preparation, cover letters, other written materials
and interview and networking training.
After accepting this Agreement, and after obtaining your manager’s approval, you may begin utilizing
outplacement services on a limited basis prior to your Employment Separation Date, consistent with the
needs of the business and your responsibilities to complete and/or transition your work. Note that you
must begin utilizing outplacement services within 45 days of your Employment Separation Date to be
eligible for this benefit.
Special rules apply to Gillette Heritage Employees with regard to retiree medical eligibility and the retiree medical cost sharing under the retiree medical plan.
If you are a Gillette Heritage Employee, you will receive a separate handout on your retiree medical eligibility.
1
1

-- 32 of 67 --

Retraining: 	[Not Applicable].
No Consideration Without Executing
this Agreement:
You affirm that you understand and agree that you would not receive the separation payment and/or
benefits specified in this Agreement without executing this Agreement and fulfilling the promises
contained in it. Except as provided in this Agreement or under the terms and conditions of an
applicable benefit plan or policy sponsored by P&G, you shall not be due any payments or benefits
from P&G in connection with your separation from employment.
Continued Employment Through
Your Employment Separation Date:
You agree to perform your work and responsibilities as an employee in a satisfactory manner up to and
including your Employment Separation Date, including compliance with all provisions of this
“Separation Agreement and Release.” If P&G determines that you have engaged in misconduct during
your employment, you understand and agree that P&G may terminate your employment immediately
and will not provide, nor will it be obligated to provide, you with the Separation payment, medical
benefits, outplacement, retraining and other benefits described above. If you have already received any
such pay or benefits, you agree to repay them to P&G upon demand.
No Admission of Wrongdoing: 	You affirm that you understand and agree that neither this Agreement nor the furnishing of the
consideration for this Agreement, including the Separation Payment, shall be deemed or construed at
any time for any purpose as an admission by P&G of wrongdoing or evidence of any liability or
unlawful conduct of any kind.

-- 33 of 67 --

Release of Claims – Including Age
Discrimination and Employment
Claims:
[If the Employee is a resident of: California, Massachusetts, Minnesota, New Jersey, or West Virginia,
replace the language below with the State Specific language that can be found here: State Specific
Release Language.docx ]
You hereby release P&G from any and all claims or rights you may have against P&G. The term
“P&G” includes, «Company», The Procter & Gamble Company and any of its and their present, former
and future owners, parents, affiliates and subsidiaries, and its and their directors, officers, shareholders,
employees, agents, benefit plans, trustees, fiduciaries, servants, representatives, predecessors,
successors and assigns. This release applies to claims about which you now know or may later
discover, and includes but is not limited to: (1) claims arising under the Age Discrimination in
Employment Act ("ADEA"), 29 U.S.C. § 621, et seq.; (2) claims arising under any other federal, state
or local law, regulation or ordinance or other order that regulates the employment relationship and/or
employee benefits; and (3) claims arising out of or relating in any way to your employment with P&G
or the conclusion of that employment. This release does not apply to claims that may arise after the
date you sign this letter or that may not be released under applicable law.
You are not waiving any rights you may have to: (a) your own vested accrued employee benefits under
the P&G health, welfare, or retirement benefit plans as of your Employment Separation Date; (b)
benefits and/or the right to seek benefits under applicable workers’ compensation and/or unemployment
compensation statutes; (c) pursue claims which by law cannot be waived by signing this Agreement;
(d) enforce this Agreement; and/or (e) challenge the validity of this Agreement.

-- 34 of 67 --

Governmental Agencies: Nothing in this Separation Letter & Release prohibits, prevents, or otherwise
limits you from filing a charge or complaint with or participating, testifying, or assisting in any
investigation, hearing, or other proceeding before any federal, state, or local government agency (e.g.,
EEOC, NLRB, SEC, OSHA, etc.) or in any legislative or judicial proceeding nor does anything in this
Separation Letter & Release preclude, prohibit, or otherwise limit, in any way, your rights and abilities
to contact, communicate with, or report unlawful conduct, or provide documents, to federal, state, or
local officials for investigation or participate in any whistleblower program administered by any such
agencies. In addition, nothing in this Separation Letter & Release, including, but not limited to, the
release of claims nor the confidential business information, and return of company property clauses,
prohibit you from: (1) reporting possible violations of federal or other law or regulations, including any
possible securities laws violations, to any governmental agency or entity, including but not limited to
the U.S. Department of Justice, the U.S. Securities and Exchange Commission, the Commodity Futures
Trading Commission, the U.S. Congress, or any agency Inspector General; (2) making any other
disclosures that are protected under the whistleblower provisions of federal or other law or regulations;
or (3) filing a charge or complaint or otherwise fully participating in any governmental whistleblower
programs, including but not limited to any such programs managed or administered by the U.S.
Securities and Exchange Commission, the Commodity Futures Trading Commission or the
Occupational Safety and Health Administration. You are not required to notify or obtain permission
from P&G when filing a governmental whistleblower charge or complaint or engaging or participating
in protected whistleblower activity. Moreover, nothing in this Separation Letter & Release prohibits or
prevents you from receiving individual monetary awards or other individual relief by virtue of
participating in such governmental whistleblower programs.

-- 35 of 67 --

Confidential, Proprietary, Trade
Secret Information: Subject to the “Governmental Agencies” portion of the “Release of Claims – Including Age
Discrimination and Employment Claims” above, you agree that you will not use or share any
confidential, proprietary or trade secret information about any aspect of P&G’s business with any non-
P&G employee or business entity at any time in the future. You further agree that you will not obtain,
transfer or have in your possession any confidential, proprietary or trade secret information on or after
your Employment Separation Date, even information you may have created yourself or to which you
may have contributed as a P&G employee. Confidential, proprietary or trade secret information
includes, but is not limited to, marketing and advertising plans, pricing information, upstream plans,
specific areas of research and development, project work, product formulation, processing methods,
assignments of individual employees, testing and evaluation procedures, cost figures, construction
plans, and special techniques or methods of any kind.
Notwithstanding the requirements of confidentiality contained in this section, the federal Defend Trade
Secrets Act of 2016 immunizes you against criminal and civil liability under federal or state trade secret
laws for your disclosure of trade secrets that is made i) in confidence to a federal, state, or local
government official, either directly or indirectly, or to an attorney solely for the purpose of reporting or
investigating a suspected violation of law; ii) in a complaint or other document filed in a lawsuit or
other proceeding, if such filing is made under seal; or iii) to your attorney for use in a lawsuit alleging
retaliation for reporting a suspected violation of law, provided that any document containing the trade
secret is filed under seal and you do not otherwise disclose the trade secret, except pursuant to court
order.
For the purposes of this section, it shall be conclusively presumed that you have knowledge or
information to which you were directly exposed through the actual receipt of memos or documents
containing such information or through actual attendance at meetings at which such information was
discussed or disclosed. The provisions of this section are not in lieu of, but are in addition to, your
continuing obligation to not use or disclose P&G’s trade secrets and confidential information known to
you until any particular trade secret or confidential information becomes generally known (through no
fault of yours). Information regarding products in development, in test market or being marketed or
promoted in a discrete geographic region, which information P&G is considering for a broader use,
shall not be deemed generally known until such broader use is actually commercially implemented.
Also, “generally known” means known throughout the domestic United States industry or, if you have
job responsibilities outside of the United States, the appropriate foreign country or countries’ industry.
If any restriction in this section is found by any court of competent jurisdiction or arbitrator to be
unenforceable because it extends for too long a period of time or over too great a range of activities or
in too broad a geographic area, it will be modified and interpreted to extend only over the maximum
period of time, range of activities or geographic area so that it may be enforceable.
If you are a participant in the Procter & Gamble 2009 Stock and Incentive Compensation Plan you are
also bound by the terms of Article F – Restrictions & Covenants of those plans, which are incorporated
herein by reference.
If you are a participant in the Procter & Gamble 2019 Stock and Incentive Compensation Plan or the
Procter & Gamble 2014 Stock and Incentive Compensation Plan, you are also bound by the terms of
Article 6 – Restrictions and Covenants of those plans which are incorporated herein by reference.

-- 36 of 67 --

If any restriction in this section is found by any court of competent jurisdiction or arbitrator to be
unenforceable because it extends for too long a period of time or over too great a range of activities or in
too broad a geographic area, it will be modified and interpreted to extend only over the maximum period
of time, range of activities or geographic area so that it may be enforceable.
If you are a participant in the Procter & Gamble 2009 Stock and Incentive Compensation Plan you are
also bound by the terms of Article F – Restrictions & Covenants of those plans, which are incorporated
herein by reference.
If you are a participant in the Procter & Gamble 2019 Stock and Incentive Compensation Plan or the
Procter & Gamble 2014 Stock and Incentive Compensation Plan, you are also bound by the terms of
Article 6 – Restrictions and Covenants of those plans which are incorporated herein by reference.
Non-Solicitation: 	You acknowledge, as a participant in the Procter & Gamble 2019 Stock and Incentive Compensation
Plan, the Procter & Gamble 2014 Stock & Incentive Compensation Plan, the Procter & Gamble 2009
Stock and Incentive Compensation Plan, the Procter & Gamble 2001 Stock and Incentive Plan, the
Procter & Gamble 1992 Stock Plan, and/or the Gillette Company 2004 Long-Term Incentive Plan that
you are bound to comply with the Plans’ non-solicitation obligations. Specifically, you agree that you
will not, for 5 years following your Employment Separation Date, attempt to directly or indirectly
induce any employee of P&G or its affiliates or subsidiaries to be employed or perform services
elsewhere or attempt directly or indirectly to solicit the trade or business of any current or prospective
customer, supplier or partner of P&G or its affiliates or subsidiaries.

-- 37 of 67 --

Acknowledgements and
Affirmations:
Subject to the “Governmental Agencies” portion of the “Release of Claims – Including Age
Discrimination and Employment Claims” above, you affirm that you have not filed, caused to be filed,
or presently are a party to any claim against P&G.
You affirm that you have been paid and/or have received all compensation, wages, bonuses,
commissions, and/or benefits which are due and payable as of the date you sign this Agreement. To the
extent that you are required to report hours worked, you affirm that you have reported all hours worked
as of the date you sign this Agreement.
You affirm that you have been granted any leave to which you were entitled under the Family and
Medical Leave Act or related state or local leave or disability accommodation laws.
You further affirm that you have no known workplace injuries or occupational diseases that have not
been reported.
Assignment of Intellectual Property: You will promptly and fully disclose, transfer and assign to P&G all inventions and any other intellectual
property (collectively “Intellectual Property”) made or conceived by you during your employment with
P&G. You agree to fully cooperate in executing any papers required for establishing or protecting the
Intellectual Property and for establishing P&G’s ownership, even if such cooperation is necessary after
your Employment Separation Date.
Return of P&G Property: 	You agree that by your Employment Separation Date, you will return to P&G in good condition all of
its equipment, materials and information that were in your possession, custody or control (including, but
not limited to, work product, notes, files, memoranda, instructional or personnel manuals, computers,
phones, iPads, tablets files, documents, credit cards, keys and identification badges). You further agree
that you will provide your manager with all passwords to P&G electronic communication and data
systems before your Employment Separation Date.
You understand and agree that technical, product, business, financial, personnel, and other physical or
personal property that you received, prepared, or helped to prepare in connection with your employment
with P&G, is P&G property and must be returned to P&G prior to your Employment Separation Date.
You further understand and agree that if P&G later discovers that you retained and/or forwarded to
yourself P&G property, you will have violated the terms of this Separation Letter & Release, P&G will
not be obligated to provide the benefits described in this Letter, and you will be required to return any
benefits received under this Separation Letter & Release.

-- 38 of 67 --

Ethics Compliance: 	Subject to the “Governmental Agencies” portion of the “Release of Claims – Including Age
Discrimination and Employment Claims” above, you agree that you provided P&G all information
known to you regarding any violations of the Procter & Gamble Worldwide Business Conduct Manual
and/or any other violations of P&G policy or the law.
Severability: 	If any court of competent jurisdiction or arbitrator should later find that any portion of this Agreement is
invalid, that invalidity will not affect the enforceability of any other portion of this Agreement.
Employment References: 	Pursuant to P&G’s standard policies, in connection with any and all potential employers seeking
references directly from P&G, you agree to refer all such reference inquiries to P&G’s employment
verification vendor. Information can be found on the GetHelp Portal by searching “Employment and
Income Verification”.
No Reliance: 	This Agreement sets forth the entire agreement between you and P&G and fully supersedes any prior
agreements or understanding between the parties except that if you are a participant in the Procter &
Gamble 2009 Stock and Incentive Compensation Plan, the terms of Article F – Restrictions & Covenants
of those plans remain in full force and effect and are incorporated herein by reference and if you are a
participant in the Procter & Gamble 2019 Stock and Incentive Compensation Plan or the Procter &
Gamble 2014 Stock and Incentive Compensation Plan, the terms of Article 6 – Restrictions & Covenants
of those plans remain in full force and are in effect and are incorporated herein by reference. In deciding
to accept this Agreement, you agree that you have not relied upon any statements or promises by P&G,
its managers, agents or employees, other than those set forth in this Agreement. No other promises or
agreements concerning the matters described in this Agreement shall be binding unless in a subsequent
document signed by these parties.
Your Attorney: 	You acknowledge that you have been and hereby are advised to consult with legal counsel before
accepting this Agreement and have either done so or have voluntarily declined to do so.

-- 39 of 67 --

Timing for Acceptance or
Revocation:
You have forty-five (45) calendar days in which to consider this Agreement in which you waive
important rights, including those under the Age Discrimination in Employment Act of 1967. If you
choose to sign this Agreement, please do so by indicating your acceptance of this Agreement with your
electronic signature in P&G’s electronic system. We advise you to consult with an attorney of your
choosing prior to signing this Agreement. Further, you may within seven (7) calendar days following
the date you accept this Agreement, cancel and terminate the Agreement by giving written notice of
your intention to revoke the Agreement to your immediate manager, and by returning to P&G any
remuneration or benefits that have been advanced to you in anticipation of your not revoking your
Agreement and to which you are not entitled. If notice of your revocation is mailed, it must be
postmarked within seven (7) calendar days after you sign this Agreement.
You agree that any modifications, material or otherwise, made to this Agreement, do not restart or affect
in any manner the original up to forty-five (45) calendar day consideration period.
Applicable Law: 	Ohio law will apply in connection with any dispute or proceeding concerning this Agreement without
regard to Ohio’s conflict of laws provisions.
The benefits described in this Agreement and pursuant to the Summary Plan Description for the Procter & Gamble Basic Separation
Program for U.S. Employees (to be obtained from your HR Business Partner), are the special benefits you will receive by signing this
Agreement. To the extent this Agreement describes benefits under other benefit plans and policies sponsored by P&G, these special benefits are
also described in the summary plan descriptions for those plans. As such, nothing in this Agreement amends or changes the terms of any P&G-
sponsored employee benefit plan or policy.
After your Employment Separation Date, you will no longer be an active P&G employee, which may affect your coverage under those plans and
policies. For example, plans may require that you enroll in Medicare to be eligible for coverage. For more information on how not being an
active P&G employee may affect your coverage, please refer to and review the summary plan descriptions for each plan.
To accept this separation package according to the terms of the above Agreement, go back to the e-mail and electronic link you received and
click on the “Accept” button. By clicking “Accept,” you acknowledge that you have read the entire Agreement, that you understand it, and that
you voluntarily accept its terms. You further agree that you understand that it is a legally binding agreement, that you have been advised to
consult with an attorney, that you have been given 45 days to consider the Agreement, and that you can revoke your acceptance within seven
days of accepting the Agreement by providing written notification to your immediate manager. If you do not wish to accept the terms of this
Agreement, click on the “Decline” button.

-- 40 of 67 --

Exhibit (10.2)
The Procter & Gamble Performance Stock Program Summary

-- 41 of 67 --

PERFORMANCE STOCK PROGRAM SUMMARY
(Effective July 1, 2024)
The Performance Stock Program (“PSP”) is a part of The Procter & Gamble Company’s (the “Company”) long-term incentive (“LTI”)
compensation and is designed to provide additional focus on key Company measures for top executives with senior management responsibility
for total Company results. Awards granted under the PSP (“PSP Awards”) are made pursuant to authority delegated to the Compensation &
Leadership Development Committee (the “C&LD Committee”) by the Board of Directors for determining compensation for the Company’s
principal officers and for making awards under the Procter & Gamble 2019 Stock and Incentive Compensation Plan (the “2019 Plan”) or any
successor stock plan approved in accordance with applicable listing standards.
I. ELIGIBILITY
The Chairman of the Board and/or Chief Executive Officer and those active executives at Band 6 or above as of June 1 prior to the grant date
and recommended by management are eligible to participate (“Participants”). In special circumstances such as for acquisitions or experienced
hires, the CHRO may authorize participation for Band 6 or above employees who are not active as of June 1 but are active employees as of the
grant date.
II. OVERVIEW
A significant portion of the Band 6 and above compensation is delivered through two long-term incentive programs tied to Company
performance: PSP and the Long-term Incentive Program.
Total long-term incentive compensation targets are based on relevant competitive market data considering the median total long-term
compensation of comparable positions, regressed for revenue size. The C&LD Committee establishes the Peer Group and sets compensation
targets for all Principal Officers including the CEO. The CEO approves compensation targets for non-Principal Officers (generally Band 6
managers).
The C&LD Committee determines the long-term incentive award for the CEO. The CEO recommends all other Principal Officer awards to the
C&LD Committee based on benchmarked long-term compensation targets, adjusted for business results and individual contributions attributable
to each executive and including that individual’s leadership skills. The C&LD Committee retains full authority to accept, modify, or reject these
recommendations. The CEO approves awards for participants who are not Principal Officers based on long-term compensation targets, business
results and individual contributions. Long-term incentive awards can be up to 50% above or 50% below the benchmarked target. In exceptional
cases, no award will be made. After total LTI award size is determined then approximately half of each Band 7 manager’s long-term
compensation is allocated to PSP via an Initial PSU Grant (as defined below). The remaining portion is a Long-term Incentive Program Grant.
Approximately 25% of each Band 6 manager’s total LTI is allocated to PSP with the remainder awarded under the Long-term Incentive Program.
PSP rewards Participants for Company performance against certain three-year performance goals in categories established by the C&LD
Committee. The C&LD Committee sets these performance goals for each three-year period that begins on July 1 and ends on June 30 three years
later (“Performance Period”). In the first year of each Performance Period, the C&LD Committee grants Performance Stock Units (“PSUs”) to
Participants that will vest at the end of the Performance Period based on the Company’s performance relative to the pre-established performance
goals (“Initial PSU Grant”). The number of

-- 42 of 67 --

PSUs that vest at the end of the Performance Period depends on the Company’s performance against the pre-established performance goals.
Vested PSUs, including dividend equivalents, are converted into shares of the Company’s common stock (“Common Stock”) delivered to the
applicable Participant within 60 days following the end of the Performance Period, or such later date as may be elected by the Participant in
accordance with Section 409A of the Internal Revenue Code (“Section 409A”).
III. PERFORMANCE CATEGORIES
The PSP Award is based on the Company’s performance in each of the following categories (each a “Performance Category”) and weighted as
indicated:
• Organic sales growth (percentile rank in the competitive peer group)* – 30%
• Constant currency core before-tax operating profit growth – 20%
• Core earnings per share (EPS) growth – 30%
• Adjusted free cash flow productivity – 20%
Awards will be further adjusted based on the three-year relative total shareholder return (R-TSR) of P&G compared to the competitive peer
group*. Awards will be adjusted for top quartile performance using a 125% multiplier to increase awards, and reduced for bottom quartile
performance using a 75% multiplier.
* Competitive peer group is defined in the PSP Accounting Guidelines.
Within the first 90 days of each Performance Period, the C&LD Committee sets three-year performance goals (“Performance Goals”) for each
Performance Category for such Performance Period and establishes a sliding scale to measure the Company’s performance against each
Performance Goal in each Performance Category. The C&LD Committee uses the sliding scale to establish a payout factor between 0% and
200% for each Performance Category (a “Sales Factor”, “Profit Factor”, “EPS Factor” and “Cash Flow Factor”, collectively, “Performance
Factors”). The final aggregated payout factor (including the R-TSR multiplier) may not exceed 200%.
In all cases, the C&LD Committee retains the discretion to include or exclude certain of the Performance Categories for purposes of determining
the PSP Award. The C&LD Committee may reduce or eliminate any payment if it determines that such payout is inconsistent with long-term
shareholders’ interests or incongruous with the overall performance of the company.
PSP awards will have the following terms unless otherwise approved by the C&LD Committee:
IV. THE INITIAL PSU GRANT
The C&LD Committee has the sole discretion to establish the target award (“PSP Target”) for each Participant serving as a Principal Officer. The
CEO establishes the PSP Targets for participants who are not Principal Officers. The PSP Target will be a cash amount and will be the basis for
the Initial PSU Grant. The C&LD Committee will make the Initial PSU Grant on the first business day in October (“Grant Date”) following the
beginning of each Performance Period. If the New York Stock Exchange is closed on the day of the grant, then the C&LD will establish a grant
date as soon as practical subsequent to the date previously specified for such award. The Initial PSU Grant will set forth a target and maximum
number of PSUs. The target number of PSUs will be determined by dividing the PSP Target by the closing price (“Grant Price”) of the
Company’s Common Stock on the New York Stock Exchange as of the close of business on the Grant Date, rounding to the nearest whole unit.

-- 43 of 67 --

V. PSU VESTING AND PAYMENT
After the Performance Period is complete, the C&LD Committee will establish the Payout Factors for each of the Performance Categories based
on the Company’s results versus the pre-established Performance Goals. The number of PSUs that vest will be determined by multiplying the
Performance Factors by their respective weightings, summing up the results, then applying the R-TSR multiplier if applicable. The final result
will be rounded up or down to the nearest full percentage. The resulting percentage will be applied to the number of PSUs in the Initial PSU
Grant target, including dividends that would have accumulated since the initial PSU grant on the vested units. Any resulting fractional share units
may be paid as cash, fractional shares, or rounded up to the next full share based on administrative preference of the Company. The number of
PSUs that vest may be equal to, above or below the Initial PSU Grant target depending on the Company’s performance in the Performance
Categories, but in no event more than the Initial PSU Grant maximum. Vested PSUs are converted into shares of Common Stock delivered to the
applicable Participant within 60 days following the end of the Performance Period, or such later date as may be elected by the Participant if
applicable and in accordance with Section 409A.
Participants at Band 7 and above may elect to defer delivery of the Common Stock by electing to receive Restricted Stock Units. PSP RSUs will
have the following terms unless otherwise approved by the Committee at grant:
VESTING AND SETTLEMENT: PSP RSUs will be vested on the grant date with a settlement date at least one year following the original
PSU delivery date (as elected by the Participant), are eligible for dividend equivalents, and can be further deferred in accordance with
Section 409A. These RSUs will be paid on their Original Settlement Date or the Agreed Settlement Date, except in the case of death. In the
case of death (except in France and the UK), payment will be made by the later of the end of the calendar year or two and a half months
following the date of death. For awards granted in France or the UK, the consequences of death are determined by the local plan supplement,
if applicable.
VI. SEPARATION FROM THE COMPANY (Defined terms shall have the meaning designated in the 2019 Plan or related award
documents)
If the Participant’s Termination of Employment occurs for any reason before the Vest Date then the Award will be forfeited unless one of the
conditions listed below is met. If the Participant remains employed through the Vest Date, the Award will paid on the Settlement Date. For the
purposes of this Award, termination of employment will be effective as of the date the Participant is no longer actively employed and will not be
extended by any notice period required under local law. Participants must remain in compliance with the terms and conditions set forth in the
2019 Plan, including those in Article 6.
1. Termination on Account of Death. In the event of death, the Award is not forfeited and will become deliverable on the Settlement Date
or Agreed Settlement Date, whichever is applicable.
2. Termination for a Qualified Reason Listed Below. In the event the Participant terminates employment for one of the qualified reasons
listed below, after the Grant Date but within four weeks, the Award will be forfeited. In the event of termination for one of the
qualified reasons listed below, on or after four weeks following the Grant Date, but prior to September 30 of the following year, the
award will be prorated based on the number of days the Participant remained an employee between the Grant Date and September 30
of the following year. If the termination for one of the qualified reasons listed below occurs after September 30 of the following year,
the entire award will be retained. The portion of the award that is ultimately

-- 44 of 67 --

retained will be delivered on the Settlement Date in this Award Agreement as long as the Participant remain in compliance with the
terms of the Plan and the Regulations. Qualified termination reasons are as follows:
• Retirement or Disability;
• Termination pursuant to a written separation agreement from the Company or a subsidiary that provides for equity retention;
or
• Termination in connection with a divestiture or separation of any of the Company’s businesses.
VII. CHANGE IN CONTROL
Notwithstanding the foregoing, if there is a Change in Control that meets the requirements of a change in control event under Section 409A, all
outstanding PSP Awards will vest and be paid according to Article 17 of the 2019 Stock Plan. If there is a Change in Control event that does not
meet the requirements of a change in control event under Section 409A, all outstanding PSP Awards will be settled according to the terms and
conditions set forth herein, without the application Article 17 of the 2019 Plan. “Change in Control” shall have the same meaning as defined in
the 2019 Plan or any successor stock plan approved in accordance with applicable listing standards.
VIII. GENERAL TERMS AND CONDITIONS
It shall be understood that the PSP does not give to any officer or employee any contract rights, express or implied, against any Company for any
PSP Award, or for compensation in addition to the salary paid to him or her, or any right to question the action of the Board of Directors or the
C&LD Committee.
Awards to Section 16 Officers are subject to the Dodd-Frank Recoupment Policy as adopted by the C&LD Committee, while awards to all other
Band 7 and above executives are subject to the Senior Executive Recoupment Policy as adopted by the C&LD Committee.
To the extent applicable, it is intended that the PSP comply with the provisions of Section 409A. The PSP will be administered and interpreted in
a manner consistent with this intent. Neither a Participant nor any of a Participant’s creditors or beneficiaries will have the right to subject any
deferred compensation (within the meaning of Section 409A) payable under the PSP to any anticipation, alienation, sale, transfer, assignment,
pledge, encumbrance, attachment or garnishment. Except as permitted under Section 409A, any deferred compensation (within the meaning of
Section 409A) payable to a Participant under the PSP may not be reduced by, or offset against, any amount owing by a Participant to the
Company.
This program document may be amended at any time by the C&LD Committee

-- 45 of 67 --

Exhibit (10.3)
Performance Stock Program related correspondence and terms and conditions

-- 46 of 67 --

AWARD AGREEMENT
___________________________________________________________________________________________________
%%FIRST_NAME_LAST_NAME%-%
%%EMPLOYEE_IDENTIFIER%-%
Subject: PERFORMANCE STOCK UNIT SERIES 	%%GRANT_USER_DEFINED_FIELD_2%-%
In recognition of your contributions to the future success of the business, The Procter & Gamble Company ("Company") hereby grants to you Performance
Stock Units ("PSUs") of Procter & Gamble Common Stock as follows:
Target Number of Units: 	%%TOTAL_SHARES_GRANTED,'999,999,999'%-%
Maximum Payout Percentage: 	200%
Conversion Ratio: 	1 PSU = 1 Common Share
Grant Date: 	%%OPTION_DATE,'DD-Month-YYYY'%-%
Vest Date: 	%%VEST_DATE_PERIOD1,'DD-Month-YYYY'%-%
Performance Period: 	1-July-2024 to 30-June-2027
Original Settlement Date (Shares Delivered on): 	17-August-2027
Acceptance Deadline: 	%%GRANT_USER_DEFINED_FIELD_13%-%
This Award is granted in accordance with and subject to the terms of The Procter & Gamble 2019 Stock and Incentive Compensation Plan (including any
applicable sub-plan) (the "Plan"), the Regulations of the Compensation and Leadership Development Committee of the Board of Directors ("Committee"), and
this Award Agreement, including Attachment A. Any capitalized terms used in this Agreement that are not otherwise defined herein are defined in the Plan. You
may access the Plan by activating this hyperlink: The Procter & Gamble 2019 Stock and Incentive Compensation Plan and the Regulations and Sub Plans by
activating this hyperlink: Regulations of the Committee.If you have difficulty accessing the materials online, please send an email to Execcomp.IM@pg.com
for assistance.
Voting Rights and Dividend Equivalents
As a holder of PSUs, during the period from the Grant Date until the date the PSUs are paid, each time a cash dividend or other cash distribution is paid with
respect to Common Stock, you will receive additional PSUs ("Dividend Equivalent PSUs"). The number of Dividend Equivalent PSUs will be determined as
follows: multiply the number of PSUs and Dividend Equivalent PSUs currently held by the per share amount of the cash dividend or other cash distribution on
Common Stock, then divide the result by the price of the Common Stock on the date of the dividend or distribution. These Dividend Equivalent PSUs will be
subject to the same terms and conditions as the original PSUs that gave rise to them, including performance vesting and settlement terms, except that if there is
a fractional number of Dividend Equivalent PSUs on the date the PSUs are paid, the resulting fractional share units may be paid as cash, fractional shares, or
rounded up to the nearest full share based on administrative preference of the Company. This Award represents an unfunded, unsecured right to receive
payment in the future, and does not entitle you to voting rights or dividend rights as a shareholder.
Performance Vesting
1. Your Target Number of Units indicated in this Award Agreement (the "Target Units") will vest depending upon performance during the Performance Period,
as specified below. This Award Agreement also sets forth the Maximum Payout Percentage that you may receive pursuant to this Award. Your right to receive
all, any portion of, or more than the Target Units (but in no event more than the Maximum Payout Percentage) will be contingent upon the achievement of
specified levels of certain performance goals measured over the Performance Period. The applicable performance goals and

-- 47 of 67 --

the payout factors for each performance goal applicable to your Award for the Performance Period are set forth in the PSP Performance and Payout Factors
attachment.
2. Within 60 days following the end of the Performance Period, the Committee will determine (i) whether and to what extent the performance goals have been
satisfied for the Performance Period, (ii) the number of PSUs that shall become deliverable under this Award, and (iii) whether the other applicable conditions
for receipt of shares of Common Stock in respect of the PSUs have been met. Any PSUs not approved by the Committee in accordance with this paragraph will
be forfeited and cancelled.
Vesting and Payment
If you leave the Company before the Vest Date, the Award will be forfeited unless you meet one of the conditions listed below. If you remain employed
through the Vest Date, the Award will be paid on the Original Settlement Date or Agreed Settlement Date (as defined below). For the purposes of this Award,
termination of employment will be effective as of the date that you are no longer actively employed and will not be extended by any notice period required
under local law.
1. Termination on Account of Death. In the event of death, the Award is not forfeited and will become deliverable on the Settlement Date or Agreed Settlement
Date, whichever is applicable.
2. Termination for a Qualified Reason Listed Below. In the event you terminate employment for one of the qualified reasons listed below, after the Grant Date
but before the four-week anniversary of the Grant Date, the Award will be forfeited. In the event of termination for one of the qualified reasons listed below, on
or after the four-week anniversary of the Grant Date, but prior to the one-year anniversary of the Grant Date, the award will be prorated based on the number of
days you remained an employee between the Grant Date and the one-year anniversary of the Grant Date. If the termination for one of the qualified reasons
listed below occurs after the one-year anniversary of the Grant Date, the entire award will be retained. The portion of the award that is ultimately retained will
be delivered on the Original Settlement Date or Agreed Settlement Date, whichever is applicable, as long as you remain in compliance with the terms of the
Plan and the Regulations. Qualified termination reasons are as follows:
• Retirement or Disability;
• Termination pursuant to a written separation agreement from the Company or a subsidiary that provides for equity retention; or
• Termination in connection with a divestiture or separation of any of the Company’s businesses.
Notwithstanding the foregoing, in the event of a Change in Control, this Award shall be treated according to the terms provided in the Plan.
Payment under this Award will be made in the form of Common Stock or such other form of payment as determined by the Committee pursuant to the Plan,
subject to applicable tax withholding.
Deferral Election (Applicable to participants Band 7 and above as of the Award Date)
At any time at least six months prior of the end of the Performance Period and so long as the achievement of the applicable performance goals are not yet
readily ascertainable (but in no event later than your Termination of Employment from the Company), you and the Company may agree to postpone the
Original Settlement Date to such later date ("Agreed Settlement Date") as may be elected by you, which date shall be at least five years later than the Original
Settlement Date and in accordance with Internal Revenue Code Section 409A.
This Award Agreement including Attachment A, the PSP Performance and Payout Factors, and the Stock Plan and Regulations of the Committee together
constitute an agreement between the Company and you in accordance with the terms thereof and hereof, and no other understandings and/or agreements that
have been entered by you with the Company regarding this specific Award. Unless otherwise required by local law, any legal action related to this Award,
including Article 6 of the Plan, may be brought in any federal or state court located in Hamilton County, Ohio, USA, and you hereby agree to accept the
jurisdiction of these courts and consent to service of process from said courts solely for legal actions related to this Award. You have the right to consult with a
lawyer before accepting this Award.
THE PROCTER & GAMBLE COMPANY
Bala Purushothaman
Chief Human Resources Officer

-- 48 of 67 --

IMPORTANT
By accepting this award within your E*TRADE account, you agree to be bound by the following:
1) The Procter & Gamble 2019 Stock Plan including the non-compete and non-solicitation clauses,
2) the Stock Plan Regulations of the Committee,
3) This Award Agreement including Attachment A (at end of this document),
4) any additional terms and conditions relevant to your current home and/or host market listed on the following page,
5) and the attached PSP Performance Factors and Payout Formula.

-- 49 of 67 --

Market Supplemental Information
Please review the following table for disclosures required for your home and/or host market. All Market Supplemental documents are links to the actual
documents.
Home Market 	Host Market 	Document Name
US 	US 	U.S. Non-Compete Addendum
Any 	Any 	Review disclosures related to the “All Markets” section of the following
document:
Appendix of Market Specific Terms and Conditions
Any 	Algeria, Argentina, Australia, Austria, Azerbaijan,
Bangladesh, Belgium, Bosnia & Herzegovina,
Brazil, Bulgaria, Canada, Chile, China, Columbia,
Costa Rica, Croatia, Czech Republic, Denmark,
Ecuador, Egypt, Finland, France, Germany, Hong
Kong, India, Indonesia, Ireland, Israel, Italy, Japan,
Kazakhstan, Kenya, Luxembourg, Mexico,
Morocco, Norway, Pakistan, Panama, Peru,
Philippines, Poland, Portugal, Romania, Russia,
Saudi Arabia, Serbia, Senegal, Singapore, South
Korea, South Africa, Spain, Sri Lanka, Sweden,
Switzerland, Taiwan, Thailand, Turkey, Ukraine,
United Arab Emirates, United Kingdom, Venezuela,
Vietnam
Review the specific disclosure relevant to your host location in the following
document:
Appendix of Market Specific Terms and Conditions
Any 	Canada 	PG Annual Report
Not US 	All except US 	Estate Tax Treatment
Any 	Japan 	Japan Prospectus – Part 1
Japan Prospectus – Part 2
Switzerland (Home or Host) 	Swiss Tax Treatment

-- 50 of 67 --

Attachment A
Please note that when the issue or transfer of the Common Stock covered by this Award may, in the opinion of the Company, conflict or be inconsistent with
any applicable law or regulation of any governmental agency, the Company reserves the right to refuse to issue or transfer said Common Stock and that any
outstanding Awards may be suspended or terminated and net proceeds may be recovered by the Company if you fail to comply with the terms and conditions
governing this Award.
Nature of the Award
By completing this form and accepting the Award evidenced hereby, I acknowledge that: i) the Plan is established voluntarily by The Procter & Gamble
Company ("P&G"), it is discretionary in nature and it may be amended, suspended or terminated at any time; ii) Awards under the Plan are voluntary and
occasional and this Award does not create any contractual or other right to receive future Awards, or benefits in lieu of an Award, even if Awards have been
granted repeatedly in the past; iii) all decisions with respect to future Awards, if any, will be at the sole discretion of P&G; iv) my participation in the Plan is
voluntary; v) this Award is an extraordinary item and not part of normal or expected compensation or salary for any purposes including, but not limited to,
calculating any termination, severance, resignation, redundancy, end of service payments, bonuses, long-service awards, pension or retirement benefits or
similar payments; vi) in the event that my employer is not P&G, the Award will not be interpreted to form an employment relationship with P&G; and
furthermore, the Award will not be interpreted to form an employment contract with my employer ("Employer"); vii) the future value of the shares purchased
under the Plan is unknown and cannot be predicted with certainty, may increase or decrease in value and potentially have no value; viii) my participation in
the Plan shall not create a right to further employment with my Employer and shall not interfere with the ability of my Employer to terminate my
employment relationship at any time, with or without cause; and ix) no claim or entitlement to compensation or damages arises from the termination of the
Award or the diminution in value of the Award or shares purchased and I irrevocably release P&G and my Employer from any such claim that may arise.
Data Privacy
I hereby explicitly and unambiguously consent to the collection, use and transfer, in electronic or other form, of my personal data as described in this
document by and among, as applicable, my Employer and The Procter & Gamble Company and its subsidiaries and affiliates ("P&G") for the exclusive
purpose of implementing, administering and managing my participation in the Plan.
I understand that P&G and my Employer hold certain personal information about me, including, but not limited to, my name, home address and telephone
number, date of birth, social insurance number or other identification number, salary, nationality, job title, any shares of stock or directorships held in P&G,
details of all Awards or any other entitlement to shares of stock awarded, canceled, exercised, vested, unvested or outstanding in my favor, for the purpose of
implementing, administering and managing the Plan ("Data"). I understand that Data may be transferred to any third parties assisting in the implementation,
administration and management of the Plan, that these recipients may be located in my country or elsewhere (including countries outside the European
Economic Area), and that the recipient’s country may have different data privacy laws and protections than my country. I understand that I may request a list
with the names and addresses of any potential recipients of the Data by contacting my local human resources representative. I authorize the recipients to
receive, possess, use, retain and transfer the Data, in electronic or other form, for the purposes of implementing, administering and managing my participation
in the Plan, including any requisite transfer of such Data as may be required to a broker or other third party with whom I may elect to deposit any shares of
stock acquired upon exercise or settlement of the Award. I understand that Data will be held only as long as is necessary to implement, administer and
manage my participation in the Plan. I understand that I may, at any time, view Data, request additional information about the storage and processing of Data,
require any necessary amendments to Data or refuse or withdraw the consents herein, in any case without cost, by contacting in writing my local human
resources representative. I understand, however, that refusing or withdrawing my consent may affect my ability to participate in the Plan. For more
information on the consequences of my refusal to consent or withdrawal of consent, I understand that I may contact my local human resources representative.

-- 51 of 67 --

Responsibility for Taxes
Regardless of any action P&G or my Employer takes with respect to any or all income tax, social insurance, payroll tax, payment on account or other tax-
related withholding ("Tax-Related Items"), I acknowledge that the ultimate liability for all Tax-Related Items is and remains my responsibility and that P&G
and/or my Employer (1) make no representations or undertakings regarding the treatment of any Tax-Related Items in connection with any aspect of this
Award, including the issuance, vesting or exercise, settlement, the subsequent sale of shares acquired, the receipt of any dividends or dividend equivalents or
the potential impact of current or future tax legislation in any jurisdiction; and (2) do not commit to structure the terms of the Award or any aspect of the
Award to reduce or eliminate my liability for Tax-Related Items.
Prior to exercise or settlement of an Award, I shall pay or make adequate arrangements satisfactory to P&G and/or my Employer to satisfy all withholding and
payment on account obligations of P&G and/or my Employer. In this regard, I authorize P&G and/or my Employer to withhold all applicable Tax-Related
Items from my wages or other cash compensation paid to me by P&G and/or my Employer or from proceeds of the sale of the shares. Alternatively, or in
addition, if permissible under local law, P&G may (1) sell or arrange for the sale of shares that I acquire to meet the withholding obligation for Tax-Related
Items, and/or (2) withhold in shares, provided that P&G only withholds the amount of shares necessary to satisfy the minimum withholding amount. Finally, I
shall pay to P&G or my Employer any amount of Tax-Related Items that P&G or my Employer may be required to withhold as a result of my participation in
the Plan or my purchase of shares that cannot be satisfied by the means previously described. P&G may refuse to honor the exercise and refuse to deliver the
shares if I fail to comply with my obligations in connection with the Tax-Related Items as described in this section.

-- 52 of 67 --

Exhibit (10-4)
Long-Term Incentive Program related correspondence and terms and conditions

-- 53 of 67 --

AWARD AGREEMENT
_____________________________________________________________________________________________
%%FIRST_NAME_MIDDLE_NAME_LAST_NAME%-%
%%EMPLOYEE_IDENTIFIER%-%
Subject: RESTRICTED STOCK UNIT SERIES 	%%GRANT_USER_DEFINED_FIELD_2%-%
In recognition of your contributions to the future success of the business, The Procter & Gamble Company ("Company") hereby grants to you Restricted Stock
Units ("RSUs") of Procter & Gamble Common Stock as follows:
Number of Restricted Stock Units: 	%%TOTAL_SHARES_GRANTED,'999,999,999'%-%
Grant Date Share Price: 	%%MARKET_VALUE%-%
Grant Date: 	%%OPTION_DATE,'DD-Month-YYYY'%-%
Vest Date: 	%%VEST_DATE_PERIOD1,'DD-Month-YYYY'%-%
Settlement Date (Shares Delivered on): 	%%VEST_DATE_PERIOD1,'DD-Month-YYYY'%-%
Acceptance Deadline: 	%%GRANT_USER_DEFINED_FIELD_13%-%
This Award is granted in accordance with and subject to the terms of The Procter & Gamble 2019 Stock and Incentive Compensation Plan (including any
applicable sub-plan) (the "Plan"), the Regulations of the Compensation and Leadership Development Committee of the Board of Directors ("Committee"), this
Award Agreement including Attachments and the Settlement Instructions in place as may be revised from time to time. Any capitalized terms used in this
Agreement that are not otherwise defined herein are defined in the Plan. You may access the Plan by activating this hyperlink: The Procter & Gamble 2019
Stock and Incentive Compensation Plan and the Regulations and Sub Plans by activating this hyperlink: Regulations of the Committee. If you have difficulty
accessing the materials online, please send an email to Execcomp.IM@pg.com for assistance.
Voting Rights and Dividend Equivalents
As a holder of RSUs, during the period from the Grant Date until the date the RSUs are paid, each time a cash dividend or other cash distribution is paid with
respect to Common Stock, you will receive additional RSUs ("Dividend Equivalent RSUs"). The number of Dividend Equivalent RSUs will be determined as
follows: multiply the number of RSUs and Dividend Equivalent RSUs currently held by the per share amount of the cash dividend or other cash distribution on
Common Stock, then divide the result by the price of the Common Stock on the date of the dividend or distribution. These Dividend Equivalent RSUs will be
subject to the same terms and conditions as the original RSUs that gave rise to them, including vesting and settlement terms, except that if there is a fractional
number of Dividend Equivalent RSUs on the date the RSUs are paid, the resulting fractional share unit may be paid as cash, fractional shares, or rounded up to
the nearest full share based on administrative preference of the Company. This Award represents an unfunded, unsecured right to receive payment in the future,
and does not entitle you to voting rights or dividend rights as a shareholder.
Vesting and Payment
If you leave the Company before the Vest Date, the Award will be forfeited unless you meet one of the conditions listed below. If you remain employed
through the Vest Date, the Award will be paid on the Settlement Date. For the purposes of this Award, termination of employment will be effective as of the
date that you are no longer actively employed and will not be extended by any notice period required under local law.

-- 54 of 67 --

1. Termination on Account of Death. In the event of death, the Award will be immediately and fully vested, and payment will be made by the later of the end of
the calendar year or two and a half months following the date of death.
2. Termination for a Qualified Reason Listed Below. In the event you terminate employment for one of the qualified reasons listed below, after the Grant Date
but before the four-week anniversary of the Grant Date, the Award will be forfeited. In the event of termination for one of the qualified reasons listed below, on
or after the four-week anniversary of the Grant Date, but prior to the one-year anniversary of the Grant Date, the award will be prorated based on the number of
days you remained an employee between the Grant Date and the one-year anniversary of the Grant Date. If the termination for one of the qualified reasons
listed below occurs after the one-year anniversary of the Grant Date, the entire award will be retained. The portion of the award that is ultimately retained will
be delivered on the Settlement Date in this Award Agreement as long as you remain in compliance with the terms of the Plan and the Regulations. Qualified
termination reasons are as follows:
• Retirement or Disability;
• Termination pursuant to a written separation agreement from the Company or a subsidiary that provides for equity retention; or
• Termination in connection with a divestiture or separation of any of the Company’s businesses.
Notwithstanding the foregoing, in the event of a Change in Control, payment shall be made pursuant to the terms provided in the Plan.
Payment under this Award will be made in the form of Common Stock or such other form of payment as determined by the Committee pursuant to the Plan,
subject to applicable tax withholding.
This Award Agreement, including Attachment A, the Plan and Regulations of the Committee together constitute an agreement between the Company and you in
accordance with the terms thereof and hereof, and no other understandings and/or agreements have been entered by you with the Company regarding this
specific Award. Unless otherwise required by local law, any legal action related to this Award, including Article 6 of the Plan, must be brought in any federal or
state court located in Hamilton County, Ohio, USA, and you hereby agree to accept the jurisdiction of these courts and consent to service of process from said
courts solely for legal actions related to this Award. You have the right to consult with a lawyer before accepting this Award.
THE PROCTER & GAMBLE COMPANY
Bala Purushothaman
Chief Human Resources Officer
IMPORTANT
By accepting this award within your E*TRADE account, you agree to be bound by The Procter & Gamble 2019 Stock Plan including the non-compete and
non-solicitation clauses, the Stock Plan Regulations of the Committee, this Award Agreement including Attachment A (at end of this document), and any
additional terms and conditions relevant to your current home and/or host market listed on the following page.

-- 55 of 67 --

Market Supplemental Information
Please review the following table for disclosures required for your home and/or host market. All Market Supplemental documents are links to the actual
documents.
Home Market 	Host Market 	Document Name
US 	US 	U.S. Non-Compete Addendum
Any 	Any 	Review disclosures related to the “All Markets” section of the following
document:
Appendix of Market Specific Terms and Conditions
Any 	Algeria, Argentina, Australia, Austria, Azerbaijan,
Bangladesh, Belgium, Bosnia & Herzegovina,
Brazil, Bulgaria, Canada, Chile, China, Columbia,
Costa Rica, Croatia, Czech Republic, Denmark,
Ecuador, Egypt, Finland, France, Germany, Hong
Kong, India, Indonesia, Ireland, Israel, Italy, Japan,
Kazakhstan, Kenya, Luxembourg, Mexico,
Morocco, Norway, Pakistan, Panama, Peru,
Philippines, Poland, Portugal, Romania, Russia,
Saudi Arabia, Serbia, Senegal, Singapore, South
Korea, South Africa, Spain, Sri Lanka, Sweden,
Switzerland, Taiwan, Thailand, Turkey, Ukraine,
United Arab Emirates, United Kingdom, Venezuela,
Vietnam
Review the specific disclosure relevant to your host location in the following
document:
Appendix of Market Specific Terms and Conditions
Any 	Canada 	PG Annual Report
Not US 	All except US 	Estate Tax Treatment
Any 	Japan 	Japan Prospectus – Part 1
Japan Prospectus – Part 2
Switzerland (Home or Host) 	Swiss Tax Treatment

-- 56 of 67 --

Attachment A
Please note that when the issue or transfer of the Common Stock covered by this Award may, in the opinion of the Company, conflict or be inconsistent with
any applicable law or regulation of any governmental agency, the Company reserves the right to refuse to issue or transfer said Common Stock and that any
outstanding Awards may be suspended or terminated and net proceeds may be recovered by the Company if you fail to comply with the terms and conditions
governing this Award.
Nature of the Award
By completing this form and accepting the Award evidenced hereby, I acknowledge that: i) the Plan is established voluntarily by The Procter & Gamble
Company ("P&G"), it is discretionary in nature and it may be amended, suspended or terminated at any time; ii) Awards under the Plan are voluntary and
occasional and this Award does not create any contractual or other right to receive future Awards, or benefits in lieu of an Award, even if Awards have been
granted repeatedly in the past; iii) all decisions with respect to future Awards, if any, will be at the sole discretion of P&G; iv) my participation in the Plan is
voluntary; v) this Award is an extraordinary item and not part of normal or expected compensation or salary for any purposes including, but not limited to,
calculating any termination, severance, resignation, redundancy, end of service payments, bonuses, long-service awards, pension or retirement benefits or
similar payments; vi) in the event that my employer is not P&G, the Award will not be interpreted to form an employment relationship with P&G; and
furthermore, the Award will not be interpreted to form an employment contract with my employer ("Employer"); vii) the future value of the shares purchased
under the Plan is unknown and cannot be predicted with certainty, may increase or decrease in value and potentially have no value; viii) my participation in
the Plan shall not create a right to further employment with my Employer and shall not interfere with the ability of my Employer to terminate my
employment relationship at any time, with or without cause; and ix) no claim or entitlement to compensation or damages arises from the termination of the
Award or the diminution in value of the Award or shares purchased and I irrevocably release P&G and my Employer from any such claim that may arise.
Data Privacy
I hereby explicitly and unambiguously consent to the collection, use and transfer, in electronic or other form, of my personal data as described in this
document by and among, as applicable, my Employer and The Procter & Gamble Company and its subsidiaries and affiliates ("P&G") for the exclusive
purpose of implementing, administering and managing my participation in the Plan.
I understand that P&G and my Employer hold certain personal information about me, including, but not limited to, my name, home address and telephone
number, date of birth, social insurance number or other identification number, salary, nationality, job title, any shares of stock or directorships held in P&G,
details of all Awards or any other entitlement to shares of stock awarded, canceled, exercised, vested, unvested or outstanding in my favor, for the purpose of
implementing, administering and managing the Plan ("Data"). I understand that Data may be transferred to any third parties assisting in the implementation,
administration and management of the Plan, that these recipients may be located in my market or elsewhere (including countries outside the European
Economic Area), and that the recipient’s market may have different data privacy laws and protections than my market. I understand that I may request a list
with the names and addresses of any potential recipients of the Data by contacting my local human resources representative. I authorize the recipients to
receive, possess, use, retain and transfer the Data, in electronic or other form, for the purposes of implementing, administering and managing my participation
in the Plan, including any requisite transfer of such Data as may be required to a broker or other third party with whom I may elect to deposit any shares of
stock acquired upon exercise or settlement of the Award. I understand that Data will be held only as long as is necessary to implement, administer and
manage my participation in the Plan. I understand that I may, at any time, view Data, request additional information about the storage and processing of Data,
require any necessary amendments to Data or refuse or withdraw the consents herein, in any case without cost, by contacting in writing my local human
resources representative. I understand, however, that refusing or withdrawing my consent may affect my ability to participate in the Plan. For more
information on the consequences of my refusal to consent or withdrawal of consent, I understand that I may contact my local human resources representative.

-- 57 of 67 --

Responsibility for Taxes
Regardless of any action P&G or my Employer takes with respect to any or all income tax, social insurance, payroll tax, payment on account or other tax-
related withholding ("Tax-Related Items"), I acknowledge that the ultimate liability for all Tax-Related Items is and remains my responsibility and that P&G
and/or my Employer (1) make no representations or undertakings regarding the treatment of any Tax-Related Items in connection with any aspect of this
Award, including the issuance, vesting or exercise, settlement, the subsequent sale of shares acquired, the receipt of any dividends or dividend equivalents or
the potential impact of current or future tax legislation in any jurisdiction; and (2) do not commit to structure the terms of the Award or any aspect of the
Award to reduce or eliminate my liability for Tax-Related Items.
Prior to exercise or settlement of an Award, I shall pay or make adequate arrangements satisfactory to P&G and/or my Employer to satisfy all withholding
and payment on account obligations of P&G and/or my Employer. In this regard, I authorize P&G and/or my Employer to withhold all applicable Tax-
Related Items from my wages or other cash compensation paid to me by P&G and/or my Employer or from proceeds of the sale of the shares. Alternatively,
or in addition, if permissible under local law, P&G may (1) sell or arrange for the sale of shares that I acquire to meet the withholding obligation for Tax-
Related Items, and/or (2) withhold in shares, provided that P&G only withholds the amount of shares necessary to satisfy the minimum withholding amount.
Finally, I shall pay to P&G or my Employer any amount of Tax-Related Items that P&G or my Employer may be required to withhold as a result of my
participation in the Plan or my purchase of shares that cannot be satisfied by the means previously described. P&G may refuse to honor the exercise and
refuse to deliver the shares if I fail to comply with my obligations in connection with the Tax-Related Items as described in this section.

-- 58 of 67 --

AWARD AGREEMENT
_____________________________________________________________________________________________
%%FIRST_NAME_MIDDLE_NAME_LAST_NAME%-%
%%EMPLOYEE_IDENTIFIER%-%
Subject: NON-STATUTORY STOCK OPTION SERIES 	%%GRANT_USER_DEFINED_FIELD_2%-%
In recognition of your contributions to the future success of the business, The Procter & Gamble Company ("Company") hereby grants to you an option to
purchase shares of Procter & Gamble Common Stock as follows:
Option Price per Share: 	%%OPTION_PRICE,'$999,999,999.99'%-%
Number of Shares: 	%%TOTAL_SHARES_GRANTED,'999,999,999'%-%
Grant Date: 	%%OPTION_DATE,'DD-Month-YYYY'%-%
Expiration Date: 	%%EXPIRE_DATE_PERIOD1,'DD-Month-YYYY'%-%
Vest Date: 	%%VEST_DATE_PERIOD1,'DD-Month-YYYY'%-%
Acceptance Deadline: 	%%GRANT_USER_DEFINED_FIELD_13%-%
This Award is granted in accordance with and subject to the terms of The Procter & Gamble 2019 Stock and Incentive Compensation Plan (including any
applicable sub-plan) (the "Plan"), the Regulations of the Compensation and Leadership Development Committee of the Board of Directors ("Committee"), this
Award Agreement including Attachments and the Exercise Instructions in place as may be revised from time to time. Any capitalized terms used in this
Agreement that are not otherwise defined herein are defined in the Plan. You may access the Plan by activating this hyperlink: The Procter & Gamble 2019
Stock and Incentive Compensation Plan and the Regulations and Sub Plans by activating this hyperlink: Regulations of the Committee.If you have difficulty
accessing the materials online, please send an email to Execcomp.IM@pg.com for assistance.
Vesting and Exercise
If you leave the Company before the Vest Date, the Award will be forfeited unless you meet one of the conditions listed below. If you remain employed
through the Vest Date, the Award will become exercisable on the Vest Date. If you terminate employment before the Expiration Date and prior to exercising the
Award, except for the reasons listed below, the Award will be forfeited immediately upon your termination of employment. For the purposes of this Award,
termination of employment will be effective as of the date that you are no longer actively employed and will not be extended by any notice period required
under local law.
1. Termination on Account of Death. In the event of death, the Vest Date for this Award becomes your date of death and the Award in its entirety remains
exercisable until the Expiration Date.
2. Termination for a Qualified Reason Listed Below. In the event you terminate employment for one of the qualified reasons listed below, after the Grant Date
but before the four-week anniversary of the Grant Date, the Award will be forfeited. In the event of termination for one of the qualified reasons listed below, on
or after the four-week anniversary of the Grant Date, but prior to the one-year anniversary of the Grant Date, the award will be prorated based on the number of
days you remained an employee between the Grant Date and the one-year anniversary of the Grant Date. If the termination for one of the qualified reasons
listed below occurs after the one-year anniversary of the Grant Date, the entire award will be retained. The portion of the award that is ultimately retained will
be

-- 59 of 67 --

exercisable on the Vest Date in this Award Agreement and will expire on the Expiration Date as long as you remain in compliance with the terms of the Plan
and the Regulations. Qualified termination reasons are as follows:
• Retirement or Disability;
• Termination pursuant to a written separation agreement from the Company or a subsidiary that provides for equity retention; or
• Termination in connection with a divestiture or separation of any of the Company’s businesses.
This Award Agreement, including Attachment A, the Plan and Regulations of the Committee together constitute an agreement between the Company and you in
accordance with the terms thereof and hereof, and no other understandings and/or agreements have been entered by you with the Company regarding this
specific Award. Unless otherwise required by local law, any legal action related to this Award, including Article 6 of the Plan, must be brought in any federal or
state court located in Hamilton County, Ohio, USA, and you hereby agree to accept the jurisdiction of these courts and consent to service of process from said
courts solely for legal actions related to this Award. You have the right to consult with a lawyer before accepting this Award.
THE PROCTER & GAMBLE COMPANY
Bala Purushothaman
Chief Human Resources Officer
IMPORTANT
By accepting this award within your E*TRADE account, you agree to be bound by The Procter & Gamble 2019 Stock Plan including the non-compete and
non-solicitation clauses, the Stock Plan Regulations of the Committee, this Award Agreement including Attachment A (at end of this document), and any
additional terms and conditions relevant to your current home and/or host market listed on the following page.

-- 60 of 67 --

Market Supplemental Information
Please review the following table for disclosures required for your home and/or host market. All Market Supplemental documents are links to the actual
documents.
Home Market 	Host Market 	Document Name
US 	US 	U.S. Non-Compete Addendum
Any 	Any 	Review disclosures related to the “All Markets” section of the following
document:
Appendix of Market Specific Terms and Conditions
Any 	Algeria, Argentina, Australia, Austria, Azerbaijan,
Bangladesh, Belgium, Bosnia & Herzegovina,
Brazil, Bulgaria, Canada, Chile, China, Columbia,
Costa Rica, Croatia, Czech Republic, Denmark,
Ecuador, Egypt, Finland, France, Germany, Hong
Kong, India, Indonesia, Ireland, Israel, Italy, Japan,
Kazakhstan, Kenya, Luxembourg, Mexico,
Morocco, Norway, Pakistan, Panama, Peru,
Philippines, Poland, Portugal, Romania, Russia,
Saudi Arabia, Serbia, Senegal, Singapore, South
Korea, South Africa, Spain, Sri Lanka, Sweden,
Switzerland, Taiwan, Thailand, Turkey, Ukraine,
United Arab Emirates, United Kingdom, Venezuela,
Vietnam
Review the specific disclosure relevant to your host location in the following
document:
Appendix of Market Specific Terms and Conditions
Any 	Canada 	PG Annual Report
Not US 	All except US 	Estate Tax Treatment
Any 	Japan 	Japan Prospectus – Part 1
Japan Prospectus – Part 2
Switzerland (Home or Host) 	Swiss Tax Treatment

-- 61 of 67 --

Attachment A
Please note that when the issue or transfer of the Common Stock covered by this Award may, in the opinion of the Company, conflict or be inconsistent with
any applicable law or regulation of any governmental agency, the Company reserves the right to refuse to issue or transfer said Common Stock and that any
outstanding Awards may be suspended or terminated and net proceeds may be recovered by the Company if you fail to comply with the terms and conditions
governing this Award.
Nature of the Award
By completing this form and accepting the Award evidenced hereby, I acknowledge that: i) the Plan is established voluntarily by The Procter & Gamble
Company ("P&G"), it is discretionary in nature and it may be amended, suspended or terminated at any time; ii) Awards under the Plan are voluntary and
occasional and this Award does not create any contractual or other right to receive future Awards, or benefits in lieu of an Award, even if Awards have been
granted repeatedly in the past; iii) all decisions with respect to future Awards, if any, will be at the sole discretion of P&G; iv) my participation in the Plan is
voluntary; v) this Award is an extraordinary item and not part of normal or expected compensation or salary for any purposes including, but not limited to,
calculating any termination, severance, resignation, redundancy, end of service payments, bonuses, long-service awards, pension or retirement benefits or
similar payments; vi) in the event that my employer is not P&G, the Award will not be interpreted to form an employment relationship with P&G; and
furthermore, the Award will not be interpreted to form an employment contract with my employer ("Employer"); vii) the future value of the shares purchased
under the Plan is unknown and cannot be predicted with certainty, may increase or decrease in value and potentially have no value; viii) my participation in
the Plan shall not create a right to further employment with my Employer and shall not interfere with the ability of my Employer to terminate my
employment relationship at any time, with or without cause; and ix) no claim or entitlement to compensation or damages arises from the termination of the
Award or the diminution in value of the Award or shares purchased and I irrevocably release P&G and my Employer from any such claim that may arise.
Data Privacy
I hereby explicitly and unambiguously consent to the collection, use and transfer, in electronic or other form, of my personal data as described in this
document by and among, as applicable, my Employer and The Procter & Gamble Company and its subsidiaries and affiliates ("P&G") for the exclusive
purpose of implementing, administering and managing my participation in the Plan.
I understand that P&G and my Employer hold certain personal information about me, including, but not limited to, my name, home address and telephone
number, date of birth, social insurance number or other identification number, salary, nationality, job title, any shares of stock or directorships held in P&G,
details of all Awards or any other entitlement to shares of stock awarded, canceled, exercised, vested, unvested or outstanding in my favor, for the purpose of
implementing, administering and managing the Plan ("Data"). I understand that Data may be transferred to any third parties assisting in the implementation,
administration and management of the Plan, that these recipients may be located in my country or elsewhere (including countries outside the European
Economic Area), and that the recipient’s country may have different data privacy laws and protections than my country. I understand that I may request a list
with the names and addresses of any potential recipients of the Data by contacting my local human resources representative. I authorize the recipients to
receive, possess, use, retain and transfer the Data, in electronic or other form, for the purposes of implementing, administering and managing my participation
in the Plan, including any requisite transfer of such Data as may be required to a broker or other third party with whom I may elect to deposit any shares of
stock acquired upon exercise or settlement of the Award. I understand that Data will be held only as long as is necessary to implement, administer and
manage my participation in the Plan. I understand that I may, at any time, view Data, request additional information about the storage and processing of Data,
require any necessary amendments to Data or refuse or withdraw the consents herein, in any case without cost, by contacting in writing my local human
resources representative. I understand, however, that refusing or withdrawing my consent may affect my ability to participate in the Plan. For more
information on the consequences of my refusal to consent or withdrawal of consent, I understand that I may contact my local human resources representative.

-- 62 of 67 --

Responsibility for Taxes
Regardless of any action P&G or my Employer takes with respect to any or all income tax, social insurance, payroll tax, payment on account or other tax-
related withholding ("Tax-Related Items"), I acknowledge that the ultimate liability for all Tax-Related Items is and remains my responsibility and that P&G
and/or my Employer (1) make no representations or undertakings regarding the treatment of any Tax-Related Items in connection with any aspect of this
Award, including the issuance, vesting or exercise, settlement, the subsequent sale of shares acquired, the receipt of any dividends or dividend equivalents or
the potential impact of current or future tax legislation in any jurisdiction; and (2) do not commit to structure the terms of the Award or any aspect of the
Award to reduce or eliminate my liability for Tax-Related Items.
Prior to exercise or settlement of an Award, I shall pay or make adequate arrangements satisfactory to P&G and/or my Employer to satisfy all withholding
and payment on account obligations of P&G and/or my Employer. In this regard, I authorize P&G and/or my Employer to withhold all applicable Tax-
Related Items from my wages or other cash compensation paid to me by P&G and/or my Employer or from proceeds of the sale of the shares. Alternatively,
or in addition, if permissible under local law, P&G may (1) sell or arrange for the sale of shares that I acquire to meet the withholding obligation for Tax-
Related Items, and/or (2) withhold in shares, provided that P&G only withholds the amount of shares necessary to satisfy the minimum withholding amount.
Finally, I shall pay to P&G or my Employer any amount of Tax-Related Items that P&G or my Employer may be required to withhold as a result of my
participation in the Plan or my purchase of shares that cannot be satisfied by the means previously described. P&G may refuse to honor the exercise and
refuse to deliver the shares if I fail to comply with my obligations in connection with the Tax-Related Items as described in this section.

-- 63 of 67 --

EXHIBIT 31.1
Rule 13a-14(a)/15d-14(a) Certifications
I, Jon R. Moeller, certify that:
(1) I have reviewed this quarterly report on Form 10-Q of The Procter & Gamble Company;
(2) Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the
statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this
report;
(3) Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the
financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
(4) The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in
Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-
15(f)) for the registrant and have:
a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to
ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those
entities, particularly during the period in which this report is being prepared;
b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our
supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for
external purposes in accordance with generally accepted accounting principles;
c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the
effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;
d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent
fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to
materially affect, the registrant’s internal control over financial reporting; and
(5) The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the
registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are
reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal
control over financial reporting.
/s/ JON R. MOELLER
(Jon R. Moeller)
Chairman of the Board, President and Chief Executive Officer
October 18, 2024
Date

-- 64 of 67 --

EXHIBIT 31.2
Rule 13a-14(a)/15d-14(a) Certifications
I, Andre Schulten, certify that:
(1) I have reviewed this quarterly report on Form 10-Q of The Procter & Gamble Company;
(2) Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the
statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this
report;
(3) Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the
financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
(4) The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in
Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-
15(f)) for the registrant and have:
a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to
ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those
entities, particularly during the period in which this report is being prepared;
b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our
supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for
external purposes in accordance with generally accepted accounting principles;
c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the
effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;
d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent
fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to
materially affect, the registrant’s internal control over financial reporting; and
(5) The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the
registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are
reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal
control over financial reporting.
/s/ ANDRE SCHULTEN
(Andre Schulten)
Chief Financial Officer
October 18, 2024
Date

-- 65 of 67 --

EXHIBIT 32.1
Section 1350 Certifications
Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned officer of The Procter & Gamble
Company (the “Company”) certifies to his knowledge that:
(1) The Quarterly Report on Form 10-Q of the Company for the quarterly period ended September 30, 2024 fully complies with the requirements of
Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2) The information contained in that Form 10-Q fairly presents, in all material respects, the financial conditions and results of operations of the
Company.
/s/ JON R. MOELLER
(Jon R. Moeller)
Chairman of the Board, President and Chief Executive Officer
October 18, 2024
Date
A signed original of this written statement required by Section 906 has been provided to The Procter & Gamble Company and will be retained by The Procter
& Gamble Company and furnished to the Securities and Exchange Commission or its staff upon request.

-- 66 of 67 --

EXHIBIT 32.2
Section 1350 Certifications
Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned officer of The Procter & Gamble
Company (the “Company”) certifies to his knowledge that:
(1) The Quarterly Report on Form 10-Q of the Company for the quarterly period ended September 30, 2024 fully complies with the requirements of
Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2) The information contained in that Form 10-Q fairly presents, in all material respects, the financial conditions and results of operations of the
Company.
/s/ ANDRE SCHULTEN
(Andre Schulten)
Chief Financial Officer
October 18, 2024
Date
A signed original of this written statement required by Section 906 has been provided to The Procter & Gamble Company and will be retained by The Procter
& Gamble Company and furnished to the Securities and Exchange Commission or its staff upon request.

-- 67 of 67 --